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Abstract 
 
 Structure based drug design is a rapidly advancing discipline that examines how protein 
targets structurally interact with small molecules, or known inhibitors, and then uses this 
information to lead inhibitor optimization efforts. In the case of novel inhibitors, protein 
structural information is first obtained via X-ray crystallography, NMR studies, or a combination 
of both approaches. Then, computational molecular docking is often used to screen, in silico, 
millions of small molecules and calculate the potential interactions they may have with the target 
protein’s binding pocket, in hopes of identifying novel low affinity inhibitors. By examining the 
interactions these small, low affinity, inhibitors have with the binding pocket, optimization 
efforts can be focused on maximizing interactions with “hot spots” within the pocket, thus 
leading to larger, high affinity inhibitors. A similar optimization technique can also be applied to 
known inhibitors. By examining the interactions of a known inhibitor with the binding site, new 
compounds can be designed to target “hot spots” in the binding pocket using the known 
inhibitors core structure as a starting point. The affinity of the newly designed compounds can 
then be compared to the affinity of the original inhibitor, and further rounds of optimization can 
be carried out. While simple in design, there are many challenges associated with structure based 
drug design studies, and there is no guarantee novel inhibitors will be found, but ultimately, it is 
an extremely powerful methodology that results in a much higher hit rate than other, similar, 
techniques. The work herein describes the use of structure based drug design to target several 
	   xi	  
different proteins involved in bacterial antibiotic resistance, and a protein that has been 
implicated in the development of Alzheimer’s disease. 
 The goal of the first project was to design a new PBP inhibitor based upon an existing 
scaffold, and to better understand the binding mechanism and molecular interactions between 
penicillin binding proteins and their inhibitors. PBPs are a group of proteins that catalyze the last 
steps of bacterial cell wall formation, and are the targets of the β-lactam antibiotics. Two 
compounds were designed which conjugated a ferrocene or ruthenocene group to 6-
aminopenicillinic acid, and their antibiotic properties were tested against a range of bacterial 
strains. To get a better understanding of how the 6-APA organometallic compounds interacted 
with the PBP active site, a CTX-M-14 β-lactamase model system was used for X-ray 
crystallographic studies. CTX-M-14 was chosen as its active site shares many key catalytic 
features with PBPs, and it easily, and reproducibly, yields crystals capable of diffracting to sub-
atomic (< 1.0 Å) resolution.  
I determined a 1.18 Å structure of 6-APA-Ru in complex with CTX-M-14 E166A β-
lactamase and was able to gain unprecedented details of the interactions of the ruthenocene 
group with the CTX-M active site. This structure also revealed that the compound bound in the 
CTX-M active site was actually the decarboxylated and hydrolyzed product, which was the first 
time a decarboxylated product had been captured in the CTX-M active site. A second, 0.85 Å, 
structure of CTX-M in complex with 6-APA-Ru was determined and shed light on how the 
hydrogen bonding network in the CTX-M active site changes in response to the 6-APA-Ru 
product binding. A final, 1.30 Å, structure captured the carboxylated and hydrolyzed 6-APA-Ru 
product in complex with CTX-M, which was the first time the carboxylated product had been 
captured in the CTX-M active with the catalytic Ser70 residue intact. The results show the 
	   xii	  
potential of the ruthenocene group in improving antibiotic potency, and help to better elucidate 
the changes that occur in the CTX-M active site upon inhibitor binding, while at the same time, 
telling us what changes could occur in the active site of PBPs. 
 The next project was focused on novel inhibitor discovery against several different PBPs. 
PBPs have been successfully inhibited by β-lactam antibiotics for decades, but the alarming rise 
of bacteria resistant to these antibiotics has placed increased urgency on the discovery of novel 
PBP inhibitors. A fragment based molecular docking approach was employed to virtually screen 
millions of small compounds for interactions with the targeted active sites, and then high scoring 
compounds were selected for visual inspection and inhibitory testing. Virtual screening was first 
done against Staphylococcus aureus monofunctional transglycosylase, a type of PBP. MTG 
provided a good binding pocket for virtual screening, but proved challenging to purify and 
crystallize. However, through great effort MTG crystals were eventually obtained. After repeated 
rounds of virtual screening against MTG, multiple compounds were selected for inhibition 
testing, and testing is currently ongoing. Virtual screening was also done against Pseudomonas 
aeruginosa PBP5 and PBP1a. Purification and crystallization of these proteins proved to be 
easier than MTG, and both yielded diffraction quality crystals. 
 The final project focused on virtual screening against a protein implicated in the 
development of Alzheimer’s disease, Slingshot Phosphatase 1. The brains of AD patients have 
been found to contain elevated levels of active Cofilin, and these elevated levels of active Cofilin 
may lead to the overproduction of amyloid β. Aβ overproduction, and its resulting accumulation, 
is believed to be one of the pathways that lead to AD symptoms. Cofilin is activated when it is 
dephosphorylated by SSH1, and inhibiting this activation may decrease the production of Aβ and 
the development of AD symptoms. There is no known structure of SSH1, so to perform virtual 
	   xiii	  
screening a SSH1 homology model was constructed using the homolog SSH2 as a starting point. 
Virtual screening was then performed using the SSH1 homology model and many compounds 
were selected for inhibition testing. Initial testing found several compounds that could prevent 
Cofilin dephosphorylation at levels > 10µM. However, three compounds were found to be 
exceptionally active, and could prevent Cofilin dephosphorylation at both 1 and 10 µM. One of 
these three compounds was tested directly against purified SSH1 and found to inhibit its activity, 
and reduce Aβ production. Crystallization of purified SSH1, and SSH2, was attempted in order 
to get complex structures with the three best compounds. SSH2 crystals were obtained which 
diffracted to 1.91 Å, and several initial hits were found for SSH1. Optimization of crystals for 
both proteins is currently ongoing. The SSH1 inhibitor, along with the two other highly active 
compounds, provides an excellent starting point for the development of highly potent SSH1 
inhibitors.
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Chapter 1: 
 
Introduction 
 
Bacterial Antibiotic Resistance 
 Since the first clinical use of penicillin in the 1940’s ushered in the antibiotic era, the β-
lactams have gone on to achieve enormous success as antibiotics.1,2 However, over the last two 
decades, the number of bacterial strains resistant to the antibiotics commonly used to treat them 
has increased with a concerning pace.1-4 A 2013 report by the Centers for Disease Control and 
Prevention found that each year in the United States, at least two million people acquire serious 
infections with bacteria resistant to one or more of the antibiotics designed to treat those 
infections, and that at least 23,000 people die each year as a direct result of those infections.5 The 
report also found that many more people die from other conditions that were complicated by a 
serious antibiotic resistant infection.5 A similar report by the European Centre for Disease 
Prevention and Control found that 25,000 people die each year in Europe from infections with 
antibiotic resistant bacteria.6 
The loss of life is not the only price associated with antibiotic resistant infections, as 
treating these infections add enormous costs to the healthcare system through extended hospital 
stays, additional doctor visits, and prolonged treatments with increasingly expensive drugs.5,6 
The CDC report estimated that antibiotic resistant infections cost $20 billion per year in excess 
healthcare costs, $35 billion per year in lost productivity, and are responsible for eight million 
additional hospital days per year.5 The ECDC found similar results in Europe, with antibiotic 
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resistant infections resulting in EUR 1.5 billion of extra healthcare costs and productivity losses 
each year.6 
 The incidence of antibiotic resistance varies among different bacteria, but is increasing 
rapidly worldwide. In the United States, studies have found upwards of 60% of Staphylococcus 
aureus isolates in the hospital to be resistant to methicillin, and several studies in different 
countries have found similar results.2,4,7,8 In Pakistan, 50-60% of community acquired Gram-
negative pathogens have become resistant to common β-lactam antibiotics, and a study in South 
Africa found 72% of Klebsiella pneumoniae isolates were suggestive of extended spectrum β-
lactamase production.4 Bacterial resistance is not only increasing against the β-lactam antibiotics, 
but against other families of antibiotics as well.  Increased resistance to polymyxin drugs, such as 
colistin and polymyxin B, has been reported in multiple countries, such as South Korea, Italy, 
Greece, and Saudi Arabia, and a study in India found 30% of Escherichia coli isolates were 
resistant against injectable antibiotics such as aminoglycosides.4 There is also widespread 
resistance to quinolone antibiotics, even though they are synthetic and do not arise in nature.4 
 The most important contributing factor to bacterial antibiotic resistance is the overuse of 
antibiotics in today’s society.2,4,5 Antibiotics are among the world’s most commonly prescribed 
and purchased drugs, but upwards of 50% of all prescribed antibiotics are either not needed, or 
not effective as prescribed.4,5 Antibiotics are also frequently used in agriculture as growth 
promoters for livestock, with some estimates stating that over 50% of all produced antibiotics go, 
unnecessarily, into animal feed.3-5 This constant overuse of antibiotics ultimately puts selective 
pressure on bacteria and results in the spread of resistant strains. Compounding the problem of 
resistance is the fact that as the rate of bacterial antibiotic resistance has increased, the rate of 
new antibiotic development over the same time period has plummeted.2-6 According to the CDC, 
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between 2000 and 2012 only eight new antibiotics were approved for use, and more than half of 
those were approved between 2000 and 2005.5 In comparison, a little over 20 new antibiotics 
were approved between 1990 and 1999, and almost 30 were approved between 1980 and 1989.2,5 
As bacteria continue to evolve and become increasingly resistant to current antibiotics, the need 
to find and develop new antibiotics will only grow more urgent. 
 
Alzheimer’s Disease 
 Alzheimer’s disease is the most common form of dementia, and initially presents as 
subtle failures of memory that eventually become severe and incapacitating.9,10 AD results from 
changes in the brain that cause the death, or malfunction, of neurons and leads to impairment of 
memory, changes in behavior, and the inability to think clearly.10 Other symptoms may present 
as seizures, incontinence, inability to carry out basic bodily functions, agitation, and 
hallucinations.9-11 As AD progresses to the final stages, patients often become bed-bound and 
require around the clock care, with eventual death resulting from inanition, malnutrition, and 
pneumonia.9,10 The rate at which AD symptoms move along the spectrum from mild to moderate 
to severe varies from person to person, and the reason for this variance is not fully understood.9-
11 On average, a patient with AD lives about eight years after initial diagnosis, but, reflecting the 
variance in rate of progression, can range anywhere from one to 25 years depending on other 
factors.9 
 The prevalence of AD increases with age, and in 2015, there are an estimated 5.3 million 
Americans living with AD, with 5.1 million of them over the age of 65.9,10,12 In the United 
States, one in nine people age 65 and older has AD, and about one-third of people age 85 and 
older have AD.12 The number of Americans with AD will only continue to grow as the size of 
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the population age 65 and older increases, and will soon increase dramatically as the “baby 
boom” generation ages.10,12 In fact, it is estimated that by 2050, 13.8 million Americans will be 
suffering from AD, and more than half of them will be age 85 or older.12 Worldwide, the number 
of people suffering from AD is estimated to be 44.5 million, with that number increasing to 
115.4 million by 2050.13 
 Alzheimer’s disease is one of the most costly chronic diseases society encounters, with an 
estimated $226 billion spent in 2015 on care for U.S. patients with AD and other dementias.10 
According to the WHO, the worldwide cost of care for people suffering from AD and other 
forms of dementia is more than $604 billion per year.13 The reasons for this increased cost of 
care are numerous, but two main contributing factors are that people suffering from AD have 
three times as many hospital stays per year compared to the average older person, and AD 
patients typically require around the clock care once symptoms progress to the severe stages.10,13 
Around the clock care normally consists of stays in an assisted living home, nursing home, or in 
home health services, and the average costs of these services can be tremendously expensive, 
with assisted living averaging $42,000 per year, and a nursing home averaging $82,000 per 
year.10 These high costs cause many people to turn to unpaid care, such as that provided by the 
patients family, and this leads to societal costs associated with lost productivity due to the 
amount of time spent caring for AD patients each day.10,13 
 Currently, the exact mechanisms that cause AD are not fully characterized, but the 
accumulation of Aβ outside of neurons, called plaques, and the accumulation of abnormal tau 
protein inside neurons, called tangles, are two hallmarks found in the brains of AD patients, and 
both have been heavily implicated in the development of AD.10,14-17 There are no known 
treatments to prevent, stop, or reverse the progression of AD, and most therapies focus on early 
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detection and improving quality of life through active management of several factors.9,10,13 With 
the number of AD patients increasing every year, and no known treatment available, the 
pathways implicated in the formation of AD represent attractive, and urgent, targets for new drug 
discovery. 
 
Structure Based Drug Design 
 The field of structure based drug design is still relatively young, but it has experienced 
rapid growth over the last two decades, and has quickly become commonplace in the world of 
medicinal chemistry.18-23 This rapid growth is due, in large part, to the constant improvement of 
many of the techniques essential for structure based drug design such as cloning, protein 
purification, X-ray crystallography, molecular docking, and structure modeling.19,23,24 The 
increased availability, and access to, high intensity X-ray light sources and NMR sources has 
been especially critical to the advancement of structure based drug design. This fact is evident 
when looking at the number of protein structures deposited in the Protein Data Bank, as there are 
now over 110,000 structures deposited, with almost 100,000 of those structures being deposited 
within the last 15 years (Figure 1).25 Availability of increased computational power and online 
databases of small molecules has also helped to speed up the virtual screening process, and 
increase the number of compounds researchers are able to screen in silico (via computer 
simulation), leading to rapid hit detection.23,26  
 The structure based drug design workflow is relatively simple in design, and has the 
ultimate goal of developing a novel high affinity inhibitor, but can be difficult to master, as it 
requires expertise in a variety of different techniques in order to achieve a favorable end result 
(Figure 2). The first step in a structure based drug design workflow is the identification of a 
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suitable protein target and knowledge of its structure.21,23 Obtaining the structure of a protein 
entails the use of use of X-ray crystallography, NMR, homology modeling, or a combination of 
these techniques.21,23 Growing protein crystals suitable for structure determination requires 
familiarity with genetic cloning, protein production and purification, and protein crystallography 
techniques. Recent advances in each of these areas, particularly in regards to automation, have 
helped to speed up the process of structure determination.23 Instruments for protein purification 
are often set up to run complicated purification protocols automatically, and around the clock, 
greatly reducing the amount of time it takes to obtain a homogenous protein sample. Also, many 
laboratories now employ the use of sophisticated crystallization robots to screen thousands of 
potential crystallization conditions in the matter of a few hours, and thereby vastly increase the 
chances of protein crystal formation, and ultimately structure determination.27 
 Once protein structural information is obtained, either through experimental methods or 
from previously determined protein structures, this information can be used to begin novel ligand 
identification. First, a target site on the protein, such as an enzymatic active site, must be 
identified in which to search for new ligands. Once a target site is identified, ligand identification 
can be accomplished either through computational methods, such as molecular docking, or 
through high throughput screening methods.18,21,23,28 Computational methods of screening 
(virtual screening) are done by docking, in silico, libraries of potential ligands into the target site 
and then scoring, and prioritizing, them based upon their estimated interactions with the 
site.26,29,30 Prioritized compounds from molecular docking would then need to be purchased and 
experimentally tested for activity against the target site. In contrast, traditional HTS methods 
experimentally screen thousands of compounds against the target site using an assay appropriate 
for the target, and then prioritize compounds that show activity against the site.28,31 While each 
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method has its strengths and weaknesses, both virtual screening and HTS have been applied 
successfully in the field of structure based drug design.28,30 
 After identification of ligands that show activity against the target site, either through 
virtual or HTS methods, the next step is to determine the structure of these lead compounds in 
complex with their protein target, and then analyze the protein-ligand interactions.21,23 To do this, 
the ligand is crystallized in complex with the protein target. This fact demonstrates the 
importance of crystallography in structure based drug design, as protein-ligand interactions 
cannot be fully studied without the complex structure. When the complex structure is 
determined, optimization of the ligand can begin. By analyzing how the ligand binds in the target 
site, nearby residues that could facilitate favorable interactions with the ligand, and lead to higher 
affinity binding, can be specifically targeted by modifying the original ligand.21,23 Alternatively, 
compound libraries can be searched for compounds that share a high structural similarity with 
the lead compound. These structurally similar compounds can then be evaluated through either 
virtual or HTS methods. The design, or selection, of new compounds during the optimization 
process restarts the cycle of structure based drug design.21 The new compounds are tested for 
their affinity to the target site, and further optimization, experimental testing, and crystallization 
occur. The cycle of structure based drug design continues until a high affinity, target specific, 
ligand is obtained. 
 
Molecular Docking 
 Molecular docking is the processes of computationally docking small molecules to a 
binding site of interest and, since being pioneered in the 1980’s, has become a commonly used 
component of structure based drug design.29,32-34 Generally, molecular docking programs need to 
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be able to accurately predict the ligand conformation, orientation, and position in the binding 
site, and also have a way to assess the potential binding affinity of the ligand to the site.29,34 
Docking programs accomplish this task by first sampling a large number of conformations for 
each ligand being docked into the binding site, and then scoring and ranking the conformations 
based upon estimated interactions with the binding site.29,32,34  
 The process of correctly orienting and positioning docked ligands in the binding site is 
extremely challenging. Docking programs must consider six degrees of translational and 
rotational freedom of the ligand relative to the binding site, as well as the conformational degrees 
of freedom of both the ligand and binding site.32 This can lead to a massive number of potential 
binding conformations between the ligand and binding site.29,32,34 Docking programs must 
consider these degrees of freedom and accurately identify the binding conformation that best fits 
the binding site, while doing so quickly enough to allow for thousands of ligands to be evaluated 
during a given docking run.29 To do so, docking programs employ the use of sampling 
algorithms. Early sampling algorithms treated both the ligand and binding site as rigid bodies, 
and only considered the translation and orientation of the rigid ligand within the binding site 
when searching for the best conformation.32 Today, the advent of new sampling algorithms allow 
for the ligand itself to be treated as flexible and for the degrees of freedom associated with its 
flexibility to be taken into account.32 However, most sampling algorithms continue to treat the 
binding site as rigid, and sites with a high level of inherent flexibility pose a problem for most 
docking programs.32 
 While the sampling algorithm positions and orients the different conformations of the 
ligand in the binding site, the conformations are constantly scored based upon their estimated 
interactions with the binding site through the use of a scoring function.29,32,34,35 The ultimate 
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purpose of the scoring function is to determine the correct conformation of the ligand in the 
binding site, while giving an estimation of the binding affinity between the ligand and 
protein.29,34,35 There are three general types of scoring functions: force-field-based, empirical, 
and knowledge-based.29,34,35 Force-field-based scoring functions assess the non-bonded (van der 
Waals and electrostatic) interactions between a ligand and binding site, as well as account for the 
effects of solvation, and then assign a score based upon the calculated sum of these 
interactions.29,34 Empirical scoring functions break binding energy into several components, such 
as hydrogen bonding, hydrophobic contributions, and ionic interactions. Each component is 
multiplied by an experimentally derived coefficient, and then summed, to yield a final score.29,34 
Knowledge-based scoring functions determine scores based upon how closely a given ligand 
matches the binding of ligands in published structures.29,34 If an interaction occurs frequently in 
published structures, that interaction is more likely to be favorable, and ligand conformations 
displaying this interaction are more likely to be favorable in the binding site than ligand 
conformations that do not.34 
 By using the combination of sample algorithms with scoring functions, docking programs 
have a good success rate of accurately predicting the best ligand binding conformation, with the 
rate somewhere between 70-80% in most cases.29,32,35 However, the inherent complexity of 
ligand and binding site interactions means that even the best molecular docking program cannot 
account for all interactions, and the score of any particular ligand conformation cannot be used as 
the sole determinant as to whether a ligand will bind well to the target site. Typically, visual 
inspection of ligands in the binding site, used in tandem with calculated scores, will be needed to 
make a final determination. Molecular docking has been proven to be a powerful tool, and as 
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computing power and docking programs continue to improve, the applications of molecular 
docking will continue to grow. 
 
 ZINC Database 
 Compound libraries are an essential component of fragment based virtual screening, and 
the ZINC database is one of the most comprehensive. The ZINC database is a free to use and 
download, virtual compound library built from over 400 catalogs of readily available, and 
purchasable, compounds.26 The ZINC database currently contains almost 100 million 
compounds, with thousands of compounds being added weekly.36 The ZINC database was 
created to fill the need for an easy to access database of purchasable compounds to aid in virtual 
screening efforts.26 Most previous small molecule databases were expensive to acquire and many 
suffered from a lack of updates and, therefore, did not contain the most up to date compound 
information.26 These previous databases also had the issue of the compounds not being 
immediately ready to dock, and extensive computational work would often need to be done to 
prepare the entire database for docking and virtual screening.26 The compounds contained in the 
ZINC database are ready to dock and can be used immediately in virtual screening.26 The ability 
to actually purchase the compounds identified from virtual screening is key, and the ZINC 
database works closely with suppliers to maintain the most up to date information on compound 
availability. Thousands of compounds with depleted stocks are removed from the database each 
week to ensure researchers do not use commercially unavailable compounds in their virtual 
screening.26 
 Many users of the ZINC database are not interested in every single compound the 
database contains, and therefore, the database is broken down into subsets. These subsets range 
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from subsets for specific vendors, to subsets based upon compound size or chemical property.26 
Two of the most commonly used subsets are the fragment-like and lead-like subsets, containing 
compounds with a molecular weight < 250 Dalton, and between 250-300 Dalton respectively.26 
The fragment-like subset currently contains ~1.6 million compounds, while the lead-like subset 
contains over six million compounds. Depending on available computational power, virtual 
screening against a binding site using the entirety of both subsets can be performed in a matter of 
hours to a few days. Users can also upload their own molecules to the ZINC server and have 
them processed in preparation for molecular docking and virtual screening.26 
 
Fragment Based Design 
 Fragment based design was first used in the 1990’s, and since then has become a 
powerful, and commonly used, technique in molecular docking to identify new lead 
compounds.26,30,37 The overall strategy of fragment based design is to use small, low molecular 
weight compounds to target subpockets of the overall binding site, identify low affinity inhibitors 
for these subpockets, and then link or grow these low affinity inhibitors together into a large high 
affinity inhibitor (Figure 3).26,30 Fragment based design can be done experimentally, using 
traditional HTS methods, but there are multiple challenges associated with screening small 
fragments, and these challenges often make HTS of fragments impractical.30 Instead, fragment 
based design has seen the most use in the field of molecular docking, and has successfully led to 
the discovery of many lead compounds that were later linked, or grown, into high affinity 
inhibitors.30 
 When compared to HTS methods that screen much larger compounds, one of the main 
benefits of fragment based design is that it allows for a much greater, and more efficient, 
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coverage of the total chemical space due to the small size of the compounds. Fragments most 
commonly have a molecular weight in the 100-300 Dalton range, and there is estimated to be > 
1060 possible compounds in this range.30,38-41 Even when using large libraries of compounds, 
traditional HTS can only sample a small fraction of these compounds, and purchasing them can 
rapidly become cost prohibitive, while fragment based molecular docking can relatively quickly 
screen an enormous number of these compounds without the need to actually purchase them. 
Furthermore, fragment based molecular docking often gives relatively high hit rates (5%) while 
only using small compound libraries, and allows for the prioritization of compounds while 
eliminating many false positives before initial affinity testing ever takes place.30  
 
Note to Reader #1 
 Figure 2 in this chapter was previously published23 by Anderson in Chemistry and 
Biology, 10 (9), 787-797 and has been reproduced with permission (see Appendix 1). 
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Figure 1. Yearly Growth of PDB Structures. The growth of the total number of structures 
deposited in the PDB by year. The total number of structures deposited in the PDB is shown in 
red, and the number of structures deposited in each year is shown in blue.25 Data as of 7/23/15. 
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Figure 2. The Process of Structure Based Drug Design.23 The process of structure based drug design from initial choice of 
target to development of a commercial drug. 
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Figure 3. Fragment Based Molecular Docking. Fragment 
libraries are screened against subpockets of the binding site 
using molecular docking. Compounds are ranked and then 
experimentally tested. Low affinity inhibitors are selected out, 
while false positives are discarded. Through linking and 
growing, the low affinity inhibitors from subpockets are 
optimized into high affinity inhibitors targeting the entire 
binding site. 	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Chapter 2: 
Penicillin Binding Protein Inhibition and Mechanism 
 
Overview 
 Penicillin binding proteins are involved in the final steps of bacterial cell wall formation, 
and are the targets of the β-lactam antibiotics. However, the rapid emergence of antibiotic 
resistant bacteria has resulted in the need for new inhibitors, and a better understanding of the 
molecular interactions happening between PBPs and their inhibitors, so these interactions can be 
exploited for new drug discovery. Two compounds were synthesized which conjugated 6-APA 
to either a ferrocene or ruthenocene group, to determine how the addition of an organometallic 
group affected antibiotic potency of an existing scaffold, and to explore the interactions the 
organometallic group could have with the PBP active site. The addition of the organometallic 
groups was found to increase antibacterial activity over the existing scaffold, 6-APA, alone. To 
study the interactions the organometallic groups had within the active site, 6-APA-Ru (Figure 
4a) was crystallized with CTX-M-14 E166A β-lactamase. CTX-M was chosen as its active site 
shares many key catalytic features with the PBPs, and it yields high-quality crystals, capable of 
diffracting to sub-Angstrom resolution (< 1.0 Å). The determination of three crystal structures 
(1.18, 0.85, and 1.30 Å) showing hydrolyzed 6-APA-Ru products (Figure 4b and 4c) in complex 
with CTX-M shed new light onto the interaction of the ruthenocene group with residues in the 
CTX-M active site, as well as changes that occur in the active site hydrogen bonding network 
during catalysis. These results provide valuable insight into the antibiotic potency of the 
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ruthenocene group, the changes that occur during substrate binding to CTX-M and subsequent 
catalysis, and what type of changes and interactions can be expected upon substrate binding to 
PBPs. 
 
Introduction 
 
 Penicillin Binding Proteins 
 Penicillin Binding Proteins are responsible for catalyzing the last steps of bacterial cell 
wall formation, and remodeling.42,43 PBPs catalyze the formation of the net-like bacterial cell 
wall though the linkage of Lipid II monomers into long glycan chains via transglycosylation, and 
then the cross-linking of the growing glycan chain via transpeptidation.44 The transglycosylation 
and transpeptidation steps are carried out by either bifunctional high molecular mass PBPs, or 
low molecular mass monofunctional PBPs.42,43 HMM PBPs have both a transglycosylase and 
transpeptidase domain, while LMM PBPs have only a singular domain and carry out only one of 
the steps.42,43 Each type of bacteria possesses a different number of PBPs, but the sequencing of 
many bacterial genomes has allowed for the number of PBPs present in most types of bacteria to 
be well established.42 Clinically, the β-lactam antibiotics have successfully inhibited the PBPs 
since penicillin was first introduced in the 1940’s. β-Lactam antibiotics react with PBPs by 
binding to the transpeptidase domain and then undergoing opening of their β-lactam ring which 
causes the formation of an acyl-enzyme adduct that remains bound to the active site and prevents 
PBPs from completing synthesis of the bacterial cell wall.45-47 
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β-lactamases 
 The marked rise in resistance to β-lactam antibiotics over the past several decades has 
been particularly facilitated by bacterial production of β-lactamases.2,48-52 β-Lactamases work by 
catalyzing the hydrolysis of the β-lactam ring through the use of a water molecule as a 
nucleophile to open the ring (Figure 5).53 Unlike PBPs, β-lactamases can catalyze the removal of 
hydrolyzed β-lactams from their active site by, in most cases, deacylating the acyl-enzyme 
adduct using the catalytic water.49,53-56 This allows β-lactamase to continuously “turn over” β-
lactam antibiotics, thereby preventing the inhibition of cell wall formation and conferring 
resistance to β-lactam antibiotics.53-56 β-lactamases are divided into four classes, A-D, with 
classes A, and C being the most commonly observed in the clinic.57 Classes A, C, and D all share 
a common active site serine residue that catalyzes the hydrolysis reaction and leads to the 
formation of an acyl-enzyme intermediate, while class B is comprised of metallo-enzymes that 
require a catalytic metal ion to function and use a reaction that does not involve an acyl-enzyme 
intermediate.53,55 Resistance to early β-lactam antibiotics led to the development of newer 
generations of β-lactams that were less susceptible to class A, C, and D β-lactamases, but 
overuse of these drugs, such as cefotaxime, has led to the emergence of extended spectrum β-
lactamases.58,59 These ESBLs have the ability to hydrolyze most current β-lactam antibiotics, and 
are mostly comprised of class A and D enzymes.58,59  
 
  CTX-M β-lactamase 
 CTX-M β-lactamase is a Class A ESBL that has the ability to hydrolyze cefotaxime, a 
third-generation, extended spectrum cephalosporin.58,59 The first CTX-M β-lactamase was 
discovered in the late 1980’s, only a few years after the clinical introduction of cefotaxime, 
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which was developed to help counter resistance to earlier generations of β-lactams.58 After its 
initial discovery, CTX-M ESBLs were found predominately in South America, Eastern Europe, 
and the Far East, with infrequent appearances in North America and Western Europe.59 
However, North America and Western Europe are starting to report increased incidence of CTX-
M, and CTX-M ESBLs have now been detected on every populated continent.58,59 There are 
currently over 40 identified CTX-M ESBLs and they have become the most frequently occurring 
ESBL worldwide.58,59 
 
  Class A β-lactamase Mechanism of Action 
 Class A β-lactamases, such as CTX-M, contain a catalytic Ser70 residue which attacks 
and forms a covalent bond with the β-lactam ring (Figure 5).60,61 The reaction pathway for the 
acylation half of β-lactam hydrolysis begins with the ground-state Michaelis complex and then 
proceeds through a high-energy acylation transition state, before forming the acyl-enzyme 
complex. The deacylation half of the reaction begins when a high-energy deacylation transition 
state is formed after a catalytic water attacks the acyl-enzyme complex, resulting in the release of 
the hydrolyzed β-lactam product.60 Class A β-lactamases can facilitate this release through 
deacylation of the intermediate by Glu166, which allows Class A β-lactamases to continuously 
hydrolyze and release the β-lactam antibiotics, leading to resistance against these drugs.60 In 
contrast, PBPs are susceptible to β-lactams as they have no mechanism to deacylate and release 
the intermediate, resulting in the inactivation of the enzyme. 
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Identity of the General Base 
 The Class A β-lactamase acylation mechanism has been intensely studied, but several key 
questions about the mechanism still remain. First, the identity of the general base that 
deprontates Ser70 in the acylation step is debated, with two main ideas persisting.60-62 One theory 
proposes that Lys73 serves as the general base, while the other proposes Glu166 as the general 
base.60-62 The Lys73 theory suggests that a neutral Lys73 deprotonates a nucleophilic Ser70, and 
then Ser70 attacks the β-lactam substrate and forms the acyl-enzyme intermediate.60 Conversely, 
the second theory suggests that Glu166 acts through a catalytic water, and serves as the catalytic 
base.60 In 2007, a study using ultra-high resolution X-ray crystallography showed that Glu166 
was likely the general base.60 However, a recently published 2015 study contradicts this result, 
and shows that Lys73, and not Glu166, acts as the general base.62 The 2015 study by Nichols et 
al., solved sub-Angstrom structures of CTX-M β-lactamase that captured the first three steps of 
the Class A β-lactamase reaction pathway.62  
The first structure, 0.79 Å apo protein of CTX-M-14, showed that Ser70 accepts a 
hydrogen bond from a protonated Lys73, and then Ser70 becomes a hydrogen bond donor to the 
catalytic water, which leads to the catalytic water serving as a hydrogen bond donor to Glu166.62 
These findings agree with a previously published 0.88 Å apo structure of CTX-M-9, which 
proposed Glu166 as the general base.60 However, the hydrogen bonding network found in the 
0.79 Å apo protein differs from the hydrogen bonding network found in a second 0.89 Å non-
covalent complex structure. Upon non-covalent ligand binding, Ser70 transfers its proton to the 
catalytic water, and the water transfers its proton to Glu166, resulting in a neutral Glu166.62 
Lys73 then establishes a short (2.53 Å in length) hydrogen bond with Ser70, with the shared 
hydrogen equidistant from the two heteroatoms.62 This observation is consistent with a previous 
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QM/MM study suggesting that a series of protonation state changes would occur upon substrate 
binding, enabling a neutral Lys73 to function as the actual general base during the acylation step, 
and not Glu166.62 
 
  Source of the General Acid Proton 
The second main question that still remains about the Class A β-lactamase acylation 
mechanism is in regards to the general acid. During catalysis, the ring nitrogen of the substrate 
must accept a proton for scission of the C-N bond to occur, and allow for the formation of the 
acyl-enzyme.63 The role of Ser130 as this proton donor to the ring nitrogen is generally accepted, 
however, the ultimate source of the proton Ser130 donates is unknown, with both Lys73 and 
Lys234 suggested to fulfill this role.60,63-65 Previous QM/MM studies have predicted that upon 
substrate binding, and during the formation of the acyl-enzyme transition state, both Lys73 and 
Lys234 will serve as a hydrogen bond donor to Ser130 in their respective interactions.63 In 
particular, as the reaction progresses, Lys73 undergoes a small conformational change that brings 
it closer to Ser130.63 After undergoing this conformational change, Lys73 donates a proton to 
Ser130, which in turn donates the proton to the ring nitrogen and results in the formation of the 
acyl-enzyme.63 While QM/MM studies have predicted Lys73 as the ultimate source of the proton 
Ser130 donates, experimental confirmation of this interaction has yet to be accomplished. 
 
Low-Barrier Hydrogen Bonds 
A LBHB is a special type of hydrogen bond that occurs when two functional groups 
equally share a proton, resulting in an unusually short (~2.5 Å) bond, with a strength 2-5 times 
stronger than a standard hydrogen bond.66 It is generally accepted that a LBHB requires the two 
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hydrogen bonding functional groups to have similar pKa’s, and for the desolvation of the active 
site to occur upon substrate binding, although the latter requirement tends to be an area of 
disagreement.66 Low-barrier hydrogen bonds have been proposed to play an important role in 
enzyme catalysis,67-71 but had eluded direct observation by X-ray crystallographic methods until 
Nichols et al. observed a LBHB between Ser70 and Lys73 in their 0.89 Å non-covalent complex 
structure.62 It was previously hypothesized that a LBHB could form between the general base 
and the nucleophilic serine, and this would stabilize the activated serine during its attack on the 
substrate.66 This interaction is observed between Ser70 and Lys73 in the 0.89 Å non-covalent 
complex by Nichols et al., and the LBHB satisfies the two main requirements for LBHB 
formation.62 This raises questions as to how exactly LBHBs form in the active site and, 
specifically, whether desolvation of the active site by ligand binding alone is sufficient for 
inducing LBHB formation, or if the formation of the LBHB is substrate specific. 
 
Metallocenes 
 Ferrocene and ruthenocene are organometallic compounds belonging to the so-called 
metallocene complexes.72 This class of molecules consists of a metal center sandwiched between 
two cyclopentadienyl rings, and has chemical properties similar to aromatic compounds.72 
Ferrocene is an archetypical metallocene and its medicinal applications have been intensely 
studied, mainly in relation to anti-cancer activity.73-79 Conversely, the biological properties of 
ruthenocene derivatives have been investigated to a much lesser extent, and only a few 
ruthenocene based compounds have appeared in drug discovery efforts.78 With the increasing 
problem of bacterial resistance and the ensuing race to find new inhibitors, the antibacterial 
properties of these organometallic groups are starting to be investigated more intensely.76 
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Results and Discussion 
 
 Antibacterial Activity of Designed Compounds 
 The antibacterial properties of 1 (Figure 4a) were tested against Gram-positive 
methicillin-sensitive Staphylococcus aureus (MSSA), methicillin-resistant S. aureus (MRSA), S. 
epidermidis, Enterococcus faecalis, and 12 clinically isolated Staphylococcus strains (Table 1). 
This screening revealed a noticeable antibacterial activity of compound 1 against the majority of 
the bacterial strains tested. The highest activity was observed against S. aureus ATCC® 29213™ 
with an MIC value of 2.0 µg ml−1, and S. epidermidis ATCC® 12228™ with an MIC value of 
4.0 µg ml−1. For comparison, the MIC values of ampicillin against these two bacterial strains are 
0.5 and 5.0 µg ml−1 respectively. While 1 was unable to reach the level of inhibition seen with 
ampicillin against the MRSA strain, the addition of the ruthenocene moiety to 6-APA showed 
much higher levels of inhibition than 6-APA alone (Table 1). The addition of the ruthenocene 
moiety also showed greater inhibition than the 6-APA ferrocene conjugate,80 indicating that the 
larger ruthenium ion may confer more potent antibacterial properties than the smaller iron ion. 
Compound 1 was also tested in vitro for hemolytic activity, and no activity was observed on 
human erythrocytes, which is one of the conditions for safe antibiotic use. To date, compound 1 
represents one of the most active ruthenocene conjugated antibiotics.81 
 
X-Ray Crystallographic Studies 
 To understand the molecular interactions occurring between the ruthenocene group and 
protein residues, compound 1 was crystallized in complex with CTX-M-14 E166A β-lactamase. 
CTX-M was chosen as its active site shares many key catalytic features with that of the PBPs, 
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51,82,83 and it yields high-quality crystals, capable of diffracting to sub-atomic resolution (< 1.0 
Å).60 The E166A mutation further increases the similarity of the CTX-M active site to that of 
PBPs by hampering deacylation in the active site, as Glu166 serves as the general base for the 
deacylation reaction, and its removal can trap the hydrolyzed product in its acyl-enzyme form.84 
Three crystal structures were determined measuring 1.18 (Table 2), 0.85, and 1.30 Å, with each 
providing new insights into the interaction of the ruthenocene group with protein residues in the 
active site, as well as the changes that occur in the active site hydrogen bonding network upon 
substrate binding and during catalysis. 
 
  6-APA-Ru Product Binding to CTX-M 
 Upon examination of the first 1.18 Å crystal structure (PDB 4XXR), the density for a 
compound was clearly visible in the active site (Figure 6a) for both monomers of CTX-M in each 
crystallographic asymmetric unit. The E166A mutation was expected to trap compound 1 in the 
acyl-enzyme state with a covalent bond between the compound and the catalytic Ser70. 
However, this acyl-enzyme form is not what was observed in the active site, possibly because the 
slightly basic pH (7.9) in our buffer sped up the deacylation process, whereas an acidic pH (4.5) 
was used in previous studies that observed the acyl-enzyme.84 Instead, an interesting hydrolyzed 
product was observed (3, Figure 4c), where the carboxylate group formed from the opening of 
the β-lactam was not present. While this decarboxylated β-lactam product has been characterized 
in studies focusing on the degradation of penicillin,85-88 there is no information about its 
interaction with β-lactamase. Previous crystallographic analysis using inactive CTX-M S70G or 
AmpC S64G mutants have only shown that the original product (similar to 2, Figure 4b) with the 
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newly generated carboxylate group would be expelled from the active site due to steric clashes 
and electrostatic repulsion.89,90 
 Upon examining the binding of 3 to CTX-M, 3 was found to form many favorable 
interactions with the active site residues and binds deeply in the pocket. The 6-APA portion of 3 
forms hydrogen bonds with Asn104, Ser130, Thr235, and Ser237, as well as a water mediated 
interaction with Arg276. The bulky ruthenocene moiety further stabilizes the compound in the 
active site by stacking against the protein backbone, including the peptide bonds of Gly238-
Asp240, and Asn170-Thr171. In addition, the ruthenocene moiety sits atop Pro167, forming 
favorable non-polar interactions. The fact that only the decarboxylated product is observed in the 
active site, as well as the seemingly favorable interactions it has with the active site, raises an 
interesting question as to whether the decarboxylated product can serve as a β-lactamase 
inhibitor. Further analysis is underway, but the decarboxylated product may provide a starting 
scaffold for inhibitor discovery against β-lactamase. 
 Close examination of the 1.18 Å CTX-M crystal structure also revealed four other 
product molecules bound to the protein outside of the active site and at the crystal-packing 
interface. Two of these product molecules still had the carboxylate group that was missing from 
the compounds in the active site (Figure 6b). It should also be noted that one of these two 
molecules (not shown) has a different chirality at the C5 atom on the five-membered ring 
compared with 2 and 3, suggesting the original stock compound used to generate 1 may contain 
some enantiomeric impurity. Nevertheless, this 1.18 Å structure demonstrates that both the 
carboxylated (2) and decarboxylated (3) products are present in solution, and that the 
decarboxylated product binds preferentially to the active site. This is consistent with the 
hypothesis that steric clashes and electrostatic repulsion, caused by the newly generated 
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carboxylate group, expel the original hydrolyzed product (2) from the active site during β-lactam 
hydrolysis.89,90 In the other two compounds outside the active site, only the ruthenocene group 
was observed in the electron density, and the rest of the compound was disordered. The first of 
the “free” ruthenocene groups is in close proximity to one of the two carboxylated products 
(Figure 7) and is well defined in the electron density. The second “free” ruthenocene group is 
only weakly visible in the electron density and will be omitted from further discussion. 
 
  Interactions Between Ruthenocene and CTX-M 
 The spatial orientation of the ruthenocene groups outside the active site offer valuable 
insights into the molecular interactions involving these organometallic groups. It has been noted 
in the literature that when ruthenocene groups are crystallized Ru---H contacts occur between the 
Ru of one ruthenocene group and the H of an adjacent ruthenocene group, with the ruthenocene 
groups orienting parallel and with a half molecule shift to one another.91 This parallel with a half 
molecule shift orientation is evident between two adjacent ruthenocene groups, one from a 
carboxylated product molecule and the other from the first “free” ruthenocene group (Figure 7). 
However, the cyclopentadienyl rings are not parallel with one another between the two 
ruthenocene groups as observed in the small molecule crystal. Based upon their orientation, it 
appears that the “free” ruthenocene group is forming two Ru---H contacts with the adjacent 
carboxylated inhibitor molecule. The corresponding Ru---C distances are 4.3 and 4.4 Å, and 
when accounting for the C---H distance of 1.083 Å, the Ru---H distances are determined to be 
3.2-3.3 Å, which are in close agreement with the 3.2 Å distance found in the literature.91 
 When examining why these molecules bind away from the active site, it appears that the 
ruthenocene group is engaged in many different types of interactions with the protein, including 
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stacking interactions between the cyclopentadienyl ring and Arg191. Most interestingly, the 
carbon atoms of the cyclopentadienyl rings of one of the inhibitors are involved in several non-
polar interactions with the protein molecules. Specifically, the product molecule is sandwiched 
between two protein monomers in the crystal lattice, and its carbon atoms are within optimal 
VDW distance of Gln31 and Ala35 of one monomer, and Lys82 of another (Figure 8). The 
distances between Ru and the hydrogen atoms on these protein side chain carbons are longer 
than 3.6-3.7 Å, which is farther than those observed between ruthenocene groups (Figure 7). 
These observations, together with the non-polar features of the side chain hydrocarbon groups, 
suggest that Ru---H bonds are unlikely in this case (Figure 8). 
 
   Rotation of the Ruthenocene Cyclopentadienyl Rings 
 The high, 1.18 Å, resolution of the first crystal structure not only yielded insight as to 
what products are present in the active site, but also showed unprecedented detail about the 
cyclopentadienyl rings of the ruthenocene group. A significant twisting of the two 
cyclopentadienyl rings in four of the compounds in the crystal structure (Figure 9) was observed, 
including the “free” ruthenocene group in the partially disordered compound (Figure 7). The 
rings in both of the active site product molecules adopt a slightly staggered conformation; with 
the bottom “floating” ring being rotated either 17.1 degrees, or 22.6 degrees in relation to the top 
ring. This slightly staggered conformation is also observed in one of the carboxylated product 
molecules that bind away from the active site. Interestingly, all of the compounds that adopt the 
staggered conformation show a roughly identical degree of rotation. The other carboxylated 
product observed in the structure has its rings in an almost eclipsed conformation, with only a 
very slight 3.8 degree twist of the rings evident (Figure 9c). As shown in Figure 6b and Figure 8, 
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the ruthenocene group of this inhibitor and its adjacent linker form extensive interactions with 
the protein, including hydrogen bonds with Lys82 and non-polar interactions with multiple 
residues. The two cyclopentadienyl rings are likely forced to adopt the eclipsed conformation by 
these interactions, suggesting that the ruthenocene group can adapt to the protein environment 
and offer more flexibility in protein-inhibitor interactions in comparison to the ferrocene group. 
This can potentially explain why the ruthenocene group conferred much better antibacterial 
activity than the ferrocene group (Table 1). 
 
Insights into the CTX-M and PBP Active Site Hydrogen Bonding Network 
In order to study the changes that occur to the hydrogen bonding network in the CTX-M 
and PBP (Figure 10) active sites upon substrate binding, a 0.85 Å structure of CTX-M-14 E166A 
mutant in complex with 6-APA-Ru was determined. As was seen in the previously discussed 
1.18 Å CTX-M structure, the active site was found to contain the decarboxylated 6-APA-Ru 
product (3, Figure 4c), while the carboxylated product (2, Figure 4b) was again found to bind 
away from the active site, and at the crystal packing interface. 
 
  General Acid Catalysis in the Acylation Reaction 
During substrate catalysis in CTX-M β-lactamase, the general acid, Ser130, donates a 
proton to the substrate ring nitrogen, leading to the formation of the acyl-enzyme. The origin of 
the proton Ser130 donates to the ring nitrogen is still unknown, with both Lys73 and Lys234 
proposed to be the source.60,63-65 QM/MM studies have shown that Lys73 is likely the source of 
this proton as it undergoes a conformational shift and moves closer to Ser130 as the acylation 
reaction progresses, although experimental confirmation of this interaction remained elusive.63 
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However, the determination of the 0.85 Å CTX-M-14 E166A structure shows experimentally, 
for the first time, that Lys73 is the source of the proton that Ser130 donates to the ring nitrogen 
(Figure 11). 
When the decarboxylated 6-APA-Ru product binds to the CTX-M active site, it does so 
non-covalently, and the position of the substrate five-membered ring ends up in the same 
position as in the covalent acyl-enzyme complex. This provides an excellent model system to 
gain insights into the hydrogen bonding network after the general acid proton transfer of the 
acylation reaction has taken place. Upon examination of the 0.85 Å structure, the protons for the 
substrate ring nitrogen, Ser130, and Lys234, are all clearly visible in the electron density map 
(Figure 11).  
In Figure 11, three protons are visible on Lys234, and while no protons are observed on 
Lys73, examination of the hydrogen bonding network infers Lys73 should have two protons. 
This is in contrast to the structure of CTX-M before the general acid proton transfer has taken 
place (Nichols et al., soon to be published data, Figure 12). In the pre-transfer structure, both 
Lys234 and Lys73 each have three protons, with one of Lys73’s protons involved in a LBHB 
with Ser70. Lys234 and Lys73 also each have a proton pointed towards Ser130, suggesting they 
are both sharing a proton with Ser130 in their respective hydrogen bonds, while Ser130’s proton 
is pointed away from both Lys234 and Lys73. The pre-transfer structure also shows that Lys73 is 
much closer to Ser70 than Ser130, reflecting the LBHB between Lys73 and Ser70.  
However, in the 0.85 Å post-transfer structure, Lys73 has changed its conformation and 
moved closer to Ser130, and is no longer involved in a LBHB with Ser70. Ser130’s proton is 
now pointing directly towards Lys73, suggesting that Ser130 is now donating a proton to Lys73 
in the hydrogen bond between the two residues. The proton on the ring nitrogen is also clearly 
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visible, and pointing towards the general acid, Ser130. Based upon these changes, and the fact 
that in the 0.85 Å post-transfer structure Lys73 only has two protons and not three as observed in 
the pre-transfer structure, it can be concluded that after substrate binding and general base 
catalysis where Lys73 activates Ser70, Lys73 changes its conformation and moves closer to 
Ser130, and then donates a proton to Ser130. Ser130 then donates this proton to the substrate 
ring nitrogen, leading to the formation of the acyl-enzyme. These changes were predicted by 
previous QM/MM studies, but the 0.85 Å post-transfer structure captures them experimentally 
for the first time, and shows that Lys73, and not Lys234, is the source of the proton that Ser130 
donates to the substrate ring nitrogen during the acylation reaction. 
These results also demonstrate changes that should occur in the PBP active site, due to 
the similarity of the PBP active site to the Class A β-lactamase active site (Figure 10). While 
PBPs cannot catalyze the deacylation reaction as Class A β-lactamases can, the formation of the 
acyl-enzyme occurs in an identical fashion (Figure 5). By determining the source of the general 
acid proton in CTX-M, we can infer that the lysine homologous to Lys73 in PBP will also act as 
the source of the proton to the general acid in the PBP active site. However, experimental 
validation of the proton source in PBP will be challenging, as sub-Angstrom resolution is 
typically needed to view hydrogen atoms, and to date, there is no structure of PBP in the PDB 
with such resolution. This fact demonstrates the value of the CTX-M system to the study of PBP 
catalysis, and the fortuitousness of the active site similarity between CTX-M and PBP. 
 
Low-Barrier Hydrogen Bond Formation 
Nichols et al. showed in their 0.89 Å non-covalent complex structure that a LBHB 
formed between Ser70 and Lys73, but questions remain about how this special type of hydrogen 
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bond can form, and specifically, if the desolvation of the active site upon substrate binding is 
enough on its own to facilitate formation of the LBHB.62 The 0.85 Å structure with the 
decarboxylated 6-APA-Ru product bound non-covalently provides an answer to the desolvation 
question. When looking at the 0.85 Å structure (Figure 11), there is no LBHB observed between 
Ser70 and Lys73, and Lys73 has moved closer to Ser130. The decarboxylated 6-APA-Ru is 
bound in the active site non-covalently, just as the tetrazole based inhibitor is in the 0.89 Å 
structure, and yet the LBHB is observed in the 0.89 Å structure (Figure 12), but not the 0.85 Å 
structure. Both substrates cause the desolvation of the active site upon binding, and if this alone 
were sufficient to induce LBHB formation, it would be expected that the LBHB between Ser70 
and Lys73 would be observed in both structures.  
This leads to the conclusion that desolvation of the active site alone is not sufficient for 
LBHB formation. Instead, there appears to be ligand specificity in LBHB formation, and that the 
substrate may play some role in the catalysis reaction itself. In this case, different hydrogen 
bonding contacts between Ser130 and the ligand have affected its interactions with Lys73, and 
subsequently the hydrogen bond between Lys73 and Ser70. It should also be pointed out that this 
ligand specificity most likely has functional relevance as well. A LBHB in the substrate complex 
would be beneficial for catalysis, while a LBHB in the product may have adverse effects. This is 
indeed what has been observed. The 0.89 Å complex structure has been hypothesized to mimic 
the pre-covalent Michaelis complex en route to the reaction transition state, whereas the 0.85 Å 
structure with the decarboxylated 6-APA-Ru is a special product complex. 
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Product Expulsion from the Active Site 
It has been shown that during catalysis when the β-lactam ring is opened and the 
carboxylated product formed (Figure 4b), steric clashes and electrostatic repulsion between the 
active site residues and the newly generated carboxylate group would help to expel the product 
from the active site.89,90 However, the only published structures of serine β-lactamases in 
complex with the carboxylated product have had the catalytic serine residue mutated to a 
glycine. This prevented the observation of any interactions the catalytic serine had with the 
newly generated carboxylate group.  
A 1.30 Å structure of the carboxylated 6-APA-Ru product (Figure 13) in complex with 
CTX-M-14 E166A mutant was determined, and represents the first structure of the caboxylated 
β-lactam product in complex with a serine β-lactamase where the catalytic serine residue remains 
intact. This 1.30 Å structure actually captures a mixture of products in the active site, with both 
the carboxylated and decarboxylated products present. When comparing the 1.30 Å structure to 
the previously discussed 1.18 and 0.85 Å structures of CTX-M in complex with the 
decarboxylated product, several differences can be noted (Figure 14). 
In the 1.30 Å structure, Ser70 adopts two distinct conformations, which is reflective of a 
mixture of the carboxylated and decarboxylated products in the active site. One conformation 
places Ser70 ~2.0 Å away from the product carboxylate group, while the other conformation 
places it ~3.2 Å away (Figure 15). The conformation that places Ser70 very close to the 
carboxylate group is the same conformation found in the 1.18 and 0.85 Å structures where the 
decarboxylated product is present, and would cause a steric clash with the newly generated 
carboxylate group. This means the conformation that places Ser70 further away from the 
carboxylate group is the conformation adopted when the carboxylated product is present in the 
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active site. Ser70 being pushed up and away from the carboxylate group is consistent with the 
theory of steric clashes and electrostatic repulsion aiding in removal of product from the active 
site. Lys73 also adopts two conformations in the 1.30 Å structure, with the terminal nitrogen 
pointing towards Ser70 when the carboxylated product is present (albeit without any hydrogen 
bonding contact with Ser70 due to the conformational change of Ser70), and the terminal 
nitrogen pointing towards Ser130 when the decarboxylated product is present (Figure 14). Lys73 
pointing towards Ser130 is consistent with the 1.18 and 0.85 Å structures. 
The fact that the decarboxylated product binds so readily to the active site compared to 
the carboxylated product aids in the confirmation of steric clashes and electrostatic repulsion 
helping to expel the carboxylated product from the active site. As discussed previously in the 
1.18 and 0.85 Å structures, both the carboxylated and decarboxylated 6-APA-Ru products were 
present in solution (Figure 6), and the decarboxylated product bound preferentially to the active 
site, while the carboxylated product bound away from the active site at the crystal packing 
interface. With no carboxylate group to clash with the active site residues, Ser70 specifically, the 
decarboxylated product is free to reenter the active site from solution and bind non-covalently 
thanks to many favorable interactions between the active site and the 6-APA portion of the 
product, as well as the favorable non-polar interactions the ruthenocene moiety forms (Figure 8).  
The observed clashing between Ser70 and the carboxylate group also explains why, until 
now, the carboxylated product has only been crystallized in complexes where the catalytic serine 
is mutated to a glycine. The removal of the catalytic serine confers extra space in the active site 
that can accommodate the carboxylate group without clashes, and then the favorable interactions 
with the active site allow the product to bind non-covalently. The carboxylated product could 
only be captured in the active site by soaking the 6-APA-Ru compound with the crystal for a 
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very short amount of time, and even with this short time a mixture of the carboxylated and 
decarboxylated product was still present in the active site. This suggests that the steric clash and 
electrostatic repulsion between Ser70 and the carboxylate group is strong enough to overcome 
the many favorable interactions the product forms with the active site. In the active site 
configuration with the carboxylated product, Lys73 is also involved in fewer interactions with 
other protein residues including Ser70, further suggesting that this may be an energetically 
unfavorable state. Meanwhile, a direct hydrogen bond is observed between Lys73 and the newly 
generated carboxylate group, demonstrating a role of Lys73 in facilitating the expulsion of the 
product out of the active site. The observed movement of Ser70 and Lys73 (Figure 13), along 
with the preferential binding of the decarboxylated product in the active site, seems to confirm 
the hypothesis that strong steric clashes and electrostatic repulsion between the product 
carboxylate group and the active site residues will aid in the expulsion of the product from the 
active site.  
 
 Potential Product Inhibition and New Scaffold for Drug Discovery 
The findings from all three crystal structures also raise questions about the potential of 
decarboxylated β-lactam products to serve as β-lactamase inhibitors. The three structures 
demonstrate that the decarboxylated 6-APA-Ru product binds readily to the CTX-M active site, 
and forms many favorable interactions. This suggests the decarboxylated product may be acting 
as a β-lactamase inhibitor, and a form of product inhibition may be occurring. The 
decarboxylated β-lactam scaffold may also be useful for PBP inhibition as well. Based upon the 
similarity of the CTX-M active site with PBPs, it can be expected that the decarboxylated 
scaffold would form many of the same favorable interactions with the PBP active site. However, 
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any form of product inhibition would not be significant in PBPs as they are not effective in 
deacylating the acyl-enzyme and releasing the product. Further testing will need to be done, but 
decarboxylated β-lactam products may be able to serve as scaffolds for new drug discovery 
against both β-lactamases and PBPs. 
 
Conclusions 
 In conclusion, two novel compounds were synthesized in order to test the antibacterial 
properties of different metallocene groups. The compounds conjugated a metallocene group, 
either ferrocene or ruthenocene, to a β-lactam antibiotic, 6-APA, and the antibacterial properties 
of these compounds were tested against a range of bacteria. Both the ferrocene and ruthenocene 
conjugates showed increased antibacterial properties over 6-APA alone, while the ruthenocene 
conjugate was found to have higher levels of bacterial inhibition than the ferrocene conjugate. 
The results demonstrate the potential of these metallocene groups in new drug discovery, and the 
ruthenocene compound represents one of the most active ruthenocene conjugated antibiotics to 
date. 
Although originally designed to bind to PBP, 6-APA-Ru was crystallized in complex 
with CTX-M-14 E166A β-lactamase as the CTX-M active site is very similar to the PBP active 
site, and CTX-M produces crystals capable of diffracting to sub-Angstrom resolution. A 1.18 Å 
crystal structure of the decarboxylated 6-APA-Ru product in complex with CTX-M suggested a 
form of product inhibition could be occurring, while also demonstrating the ability of the 
cyclopentadienyl rings of the ruthenocene group to rotate to better conform to the binding site. 
This structure represents the first time a decarboxylated β-lactam product has been crystallized in 
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the CTX-M active site, and also shows the first time any β-lactam product has been crystallized 
in the CTX-M active site with the catalytic serine unmutated.  
In order to better understand the changes that occur in the hydrogen bonding network 
upon substrate binding, a 0.85 Å structure of CTX-M complexed with the decarboxylated 6-
APA-Ru product was determined. This structure is the highest resolution structure of an 
organometallic compound in complex with a protein to date. The high resolution of this structure 
allowed for the viewing of individual hydrogen atoms on the CTX-M active site residues. This 
structure showed experimentally, for the first time, that Lys73 is the source of the proton that the 
general acid, Ser130, donates to the substrate ring nitrogen during the Class A β-lactamase 
acylation reaction. This solves a longstanding mystery about the source of the general acid 
proton, and adds clarity to the exact mechanism behind β-lactam acyl-enzyme formation in 
serine β-lactamases, and PBPs by extension. 
The 0.85 Å structure also provided insights into the formation of LBHBs, which were 
only recently confirmed experimentally by Nichols et al.62 While the study confirmed the 
existence of LBHBs, there were still many questions as to how they were formed, such as if 
desolvation of the active site upon substrate binding alone was sufficient to induce LBHB 
formation. The LBHB Nichols et al. observed between Ser70 and Lys73 was not observed in the 
0.85 Å structure, leading to the conclusion that desolvation of the active site alone is not enough 
to induce LBHB formation, and other factors are likely involved. Furthermore, the similarity of 
binding between the ligand used by Nichols et al. and the 6-APA-Ru ligand, as well as the 
observation of a LBHB in their structure but not in the 1.18, 0.85, or 1.30 Å structures, suggests 
that there may be some form of ligand specificity in LBHB formation, and that the ligand itself 
may play a role in this aspect of the catalysis process. 
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The determination of a 1.30 Å structure of CTX-M in complex with the carboxylated 6-
APA-Ru product provided new information about the process of product expulsion from the 
Class A β-lactamase active site. This structure captured a mixture of the carboxylated and 
decarboxylated product in the active site, and represents the first time the carboxylated β-lactam 
product has even been seen in the active site when the catalytic serine residue remains 
unmutated. Two conformations of Ser70 and Lys73 were observed in the active site of the 1.30 
Å structure, a finding consistent with having a mixture of carboxylated and decarboxylated 
product in the active site. By comparing the 1.30 Å structure to the 1.18 and 0.85 Å structures 
complexed with the 6-APA-Ru decarboxylated product, Ser70 was shown to undergo a sizeable 
shift away from the substrate carboxylate group when the carboxylated product is present, and 
Lys73 was found to point away from Ser130. The shift of these active site residues, along with 
the preferential binding of the decarboxylated product in the active site, seem to confirm the 
hypothesis that steric clashes and electrostatic repulsion between the carboxylate group and the 
active site residues will aid in expelling the carboxylated product from the active site.  
Additionally, the preferential binding of the decarboxylated product in the active site, 
along with the many favorable interactions it forms with the active site, seem to suggest the 
decarboxylated product may be acting as a β-lactamase inhibitor and that a form of product 
inhibition may be occurring. This raises questions about the ability of decarboxylated β-lactam 
products to serve as scaffolds for new drug discovery against β-lactamases and PBPs. 
Overall, the results presented in this chapter demonstrate the antibiotic potential of the 
ferrocene and ruthenocene groups, and shed new light into the hydrogen bonding network in the 
Class A β-lactamase, and PBP, active site during substrate binding. The results answer a long 
debated question about the details of the acylation mechanism, and seem to confirm several other 
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hypotheses about LBHB formation, and product expulsion from the active site. The discovery of 
a decarboxylated β-lactam product in the active site opens new doors for drug discovery against 
Class A β-lactamases and PBPs. 
 
Experimental Procedures 
 
 Compound Synthesis 
 
  General Comments 
 Synthesis of compound 1 (Figure 16) was carried out using standard Schlenk techniques. 
Chromatographic separation was carried out using silica gel 60 (Merck, 230-400 mesh ASTM). 
Dichloromethane and triethylamine were distilled and deoxygenated prior to use. Other solvents 
were of reagent grade and were used without prior purification. All other chemicals were 
purchased from the Aldrich Chemical Co. The NMR spectra were recorded on a Bruker AV600 
Kryo (600 MHz) spectrometer. Chemical shifts are reported in δ (ppm) using residual CHCl3 (1H 
δ 7.26 ppm) signal as the reference. Mass spectrum was recorded using a positive FAB method 
on a Voyager Spec mass spectrometer (cyano-4-hydroxycinnaminic acid – saturated in 0.1% 
TFA H2O/acetonitrile 1:1 as a matrix). IR spectra were recorded on a FTIR Nexus Nicolet 
apparatus. 
 
  Procedure for the Synthesis of Compound 1 
 A solution of 6-APA (108 mg, 0.50 mmol) in dichloromethane/triethylamine (10 ml:800 
µl) was added to an argon-saturated dichloromethane (10 ml) solution of 4-oxo-4-(ruthenocenyl) 
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butanoic N-succinimidyl ester (194 mg, 0.45 mmol). The reaction mixture was stirred for 18 hrs 
at room temperature. Solvents were then evaporated and the residue was subjected to column 
chromatography on SiO2 (CHCl3/MeOH, 50:5). Chromatographically purified compound 1 was 
dissolved in chloroform and washed with 3% HClaq. The organic layer was separated, dried over 
anhydrous MgSO4 and evaporated. Crystallization from a chloroform/n-hexane mixture afforded 
1 as a yellow solid with 73% yield (175 mg). 
1H NMR (600 MHz, DMSO-d6): δ = ~13 (bs, H, COOH), 8.26 (d, JHH = 8.7 Hz, 1H, NH), 5.10 
(bs, 2H, Rc), 4.91 (d, JHH = 7 Hz, 1H, H β-lactam), 4.82 (pt, JHH = 1.6 Hz, 2H, Rc), 4.64 (s, 5H, 
Rc), 4.41 (dd, JHH = 8.2H, 7.1 Hz, 1H, H β-lactam), 3.60 (s, 1H, H β-lactam), 2.84 (t, JHH = 7.6 
Hz, 2H, CH2), 2.43 (m, 2H, CH2), 1.52 (s, 3H, CH3), 1.18 (s, 3H, CH3) ppm. FAB-MS (positive 
ions): m/z = 531 (M+H+). FTIR (KBr ν [cm-1]): 3686-2142 (NH+OH), 1782 (CO), 1740 (CO), 
1663 (2CO) (Figure 17A-F). 
 
 Antibacterial Activity 
 The antimicrobial activity of compound 1 was evaluated by the minimal inhibitory 
concentrations (MIC) method using the serial two-fold dilution method under standard 
conditions as described in the Clinical and Laboratory Standards Institute reference method 
M07-A8.92 A panel of Gram-positive bacterial strains, Staphylococcus aureus ATCC® 29213TM 
(sensitive to methicillin, (MSSA)), Staphylococcus aureus ATCC® 43300TM (resistant to 
methicillin, (MRSA)), Staphylococcus epidermidis ATCC® 12228TM, Enterococcus faecalis 
ATCC® 29212TM were used. Twelve clinical isolates of methicillin sensitive Staphylococcus 
aureus (MSSA) obtained from the Department of Pharmaceutical Microbiology at the Medical 
University of Warsaw, Poland were also used. The clinical isolates were collected from various 
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patients hospitalized in several clinics. Bacterial strains were cultivated on tryptic soy agar 
according to ATCC recommendation. All strains were incubated for 24 hrs at 37° C. 
Reference method (broth microdilution susceptibility test) was as follows: compound 1 
was dissolved in DMSO. A series of two-fold compound 1 dilutions were diluted with cation–
adjusted Mueller–Hinton broth (CAMHB). Then, 95 µl aliquots were dispensed into sterile 
microdilution plates (Mar-Four), and 5 µl of bacteria inoculum, containing 5 x 104 CFU ml, was 
added. The final concentration of compound 1 ranged from 256 to 0.5 µg/ml, all in two-fold 
dilution steps. The plates were incubated at 35° C for 24 hours. Results were obtained with the 
use of Spectrostar Omega (BMG Labtech), and absorbance was measured at 540 and 595 nm. 
The experiments for each sample were conducted in triplicate. Penicillin G was used as a control 
(from 8 – 0.15 µg/ml). MIC was defined as the lowest drug concentration that reduced growth by 
100%. 
 
 Hemolysis Testing 
 The hemolysis test was performed following the literature method.93 Red blood cells 
were obtained from a healthy donor. The erythrocytes were separated from blood plasma and 
leukocytes by centrifugation (2500 g, 5 min) at 4° C, and washed three times with phosphate 
buffered saline (PBS, pH 7.4). Prepared suspension of 1% hematocrit was incubated with serial 
concentrations (0.001, 0.03, 0.15, 0.4 mM, respectively) of compound 1 for 30 min at 23° C. 
After centrifugation (1,000 rpm, 5 min) the absorbance of the supernatant was measured at 540 
nm (Jasco V-630). A value of 100% hemolysis was determined by incubation of erythrocytes 
with double-distilled water (30 min at 23° C). 
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 Protein Purification 
 The CTX-M-14 E166A gene sequence was cloned into the pET9a expression vector and 
transformed into BL21 (DE3) competent cells for protein expression. The cells were grown in 1 
liter 2XYT media containing 16 g tryptone, 10 g yeast extract, and 5 g NaCl. Before use, sorbitol 
and betaine were added to the media to a final concentration of 0.2 M and 5 mM respectively. 
Cultures were grown in the presence of 50 µg/ml kanamycin. The cultures were incubated at 37° 
C with shaking at 225 rpm until the OD600 reached 0.6-0.8. Protein expression was induced by 
the addition of 0.5 mM IPTG, and then cultures were incubated overnight at 20° C with shaking 
at 225 rpm. The total induction time was around 24 hrs. After overnight incubation, cells were 
centrifuged at 4000g for 10 min at 4° C, and then the supernatant was discarded. 
 The cell pellet was then resuspended in lysis buffer (10 mM MES pH 6.0, 2 mM EDTA). 
A protease inhibitor tablet was then crushed and dissolved in the resuspension. Cells were then 
lysed by sonication using 10 seconds ON and 15 seconds OFF at amplitude 10, for a total of 15 
min. Lysed cells were then centrifuged at 35,000 rpm for 35 min at 4° C. The supernatant was 
filtered and loaded onto a 60 ml CM-sepharose ion exchange column using Buffer A (50 mM 
MES pH 6.0, 2 mM EDTA). After loading, the column was washed with two column volumes of 
Buffer A. The protein was eluted from the column by using an increasing concentration of Buffer 
B (50 mM MES pH 6.0, 2 mM EDTA, 150 mM NaCl) from 0-100%. SDS-PAGE was used to 
verify protein containing fractions. The fractions were pooled and prepared for loading onto a gel 
filtration column.  
The pooled fractions were loaded onto a SuperDex75 16/60 gel filtration column using a 
Buffer C (10 mM Tris pH 7.0, 50 mM NaCl, 2 mM EDTA). SDS-PAGE was used to verify 
protein containing fractions, and protein purity. The protein containing fractions were pooled, 
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and concentrated to approximately 20 mg/ml. The protein was aliquoted and then flash frozen 
and stored at -80° C. 
  
 Protein Crystallization 
 CTX-M-14 E166A (20 mg/ml) was crystallized in 1.0 M potassium phosphate pH 7.9 at 
20° C using hanging drops in a 1:1 ratio (protein:buffer). Single crystals formed in 3-4 days. 10 
mM compound 1 dissolved in the crystallization buffer was then added to the crystal drops and 
allowed to soak into the crystals. Soaking times varied considerably and ranged from 4 hrs to 5 
days. After soaking, the crystals were collected and cryo-cooled using a solution of the 
crystallization buffer with 30% sucrose added. 
 
 X-Ray Data Collection and Refinement 
 Ultra-high resolution (< 1.0 Å) data was collected using the 23-ID-D beamline of 
GM/CA-CAT at the Advanced Photon Source, Argonne, Illinois. Remaining data was collected 
using the 22-ID beamline of SER-CAT at the Advanced Photon Source, Argonne, Illinois. All 
data were processed using HKL2000.94 Ultra-high resolution data were refined using SHELXL95 
and the CCP496 suite was used to refine all other data. SHELXL and Coot97 were used to 
complete the model building and refinement for the ultra-high resolution data, while Coot alone 
was used for all other data. 
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Note to Reader #1 
 Portions of this chapter have been reproduced from – E. M. Lewandowski, J. Skiba, N. J. 
Torelli, A. Rajnisz, J. Solecka, K. Kowalski and Y. Chen, Chem. Commun., 2015, 51, 6186 – by 
permission of The Royal Society of Chemistry (see Appendix 2). 
 
Note to Reader #2 
 The compound synthesis and antibacterial testing described in this chapter were carried 
out by members of the Kowalski lab at the University of Łódź in Łódź, Poland, and by members 
of the Solecka lab at the National Institute of Public Health in Warsaw, Poland. 
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Figure 4. Structure of 6-APA-Ru and Products. Structures of 1 and hydrolyzed products. a) Intact 1. b) Hydrolyzed 1, 
penicilloic acid form. c) Decarboxylated and hydrolyzed 1, penilloic acid form. 2 and 3 are termed as carboxylated and 
decarboxylated products respectively in the text.  
1 2 
3 
a) b) 
c) 
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Figure 5. Hydrolysis Mechanism of Class A β-lactamase. The reaction pathway for the acylation half of β-lactam 
hydrolysis begins with the ground-state Michaelis complex (I), and then proceeds through a high-energy acylation 
transition state (II), before forming the acyl-enzyme complex (III). The deacylation half of the reaction begins when a 
high-energy deacylation transition state is formed after a catalytic water attacks the acyl-enzyme complex (IV), 
resulting in the release of the hydrolyzed β-lactam product (V). 
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Figure 6. Hydrolyzed Products Captured In and Outside the CTX-M-14 E166A Active Site. Unbiased Fo-Fc 
maps shown in green at 3 σ. a) 3 bound in the active site. b) 2 bound outside the active site. 
His197 
Lys82 
Thr86 
Ser237 
Thr235 
Ser130 
Asn132 
Asn104 
a) 
b) 
Pro167 
Asp240 
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Figure 7. Ru---H Interactions Between Ruthenocene Groups Outside the Active Site. Ru---C contacts (at a distance 
of 4.3-4.4 Å) are shown as dashed black lines, along which the hydrogens from the cyclopentadienyl carbon atoms are 
projected. For the “free” ruthenocene (left), the rest of the compound is disordered and unmodeled.  
Gln83 
Gly147 
Gly143 
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Figure 8. Interactions of the Ruthenocene Group with Amino Acid Side Chains. Away from the active site, the ruthenocene 
group is sandwiched between two protein monomers and is held in place by several non-polar interactions. The compound is colored 
magenta, while the different protein monomers are colored yellow and green. Potential C---C interactions (at a distance of 3.8-4.2 Å) 
are shown as dashed black lines. 	  
Lys82 
Ala35 
Gln31 
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Figure 9. Twists of the Cyclopentadienyl Rings. a) Active site A, 17.1 degree twist, b) Active site B, 22.6 degree 
twist, c) Non-active site A, 3.8 degree twist, d) Non-active site B, 21.7 degree twist. 
a) b) 
c) d) 
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Lys234 
Ser130 
Ser70 
Lys73 
Glu166 
Figure 10. Structural Similarities Between CTX-M and PBP Active Sites. Conformational similarities between key active site residues 
in CTX-M-9 Class A β-lactamase (green) and Pseduomonas aeruginosa PBP5 (magenta). Residues are labeled based upon their numbering 
in CTX-M-9. Glu166 catalyzes the deacylation step of the Class A β-lactamase hydrolysis mechanism, and PBPs do not possess a homolog 
for this residue. Glu166 is labeled in red to denote this difference. 
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Figure 11. Hydrogen Bonding Network in the Active Site Post General Acid Proton Transfer.  Protons are observed on Lys234, 
Ser130 and the substrate ring nitrogen. As the general acid, Ser130 has accepted a proton from Lys73, and then donated this proton to 
the substrate ring nitrogen. Three protons are observed on Lys234, and only two protons are inferred on Lys73. Lys73 is not involved 
in a LBHB with Ser70. The proton on Ser130 is pointed towards Lys73, suggesting Ser130 is donating a proton to Lys73 in their 
hydrogen bond. Density for the protons is colored in red. CTX-M is colored in green and the decarboxylated 6-APA-Ru product is 
colored in orange. 
Lys234 
Ser130 
Lys73 
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Figure 12. Hydrogen Bonding Network in the Active Site Pre General Acid Proton Transfer. Pre general acid 
proton transfer, Lys234 and Lys73 each have three protons, with one proton of Lys73 involved in a LBHB with 
Ser70. Lys234 and Lys73 are each sharing a proton with Ser130 in their respective hydrogen bonds. The proton on 
Ser130 is pointed away from both Lys234 and Lys73. The proton shared by Lys73 and Ser70 in a LBHB is shown as 
a sphere. Density for the protons is shown in red. 
Lys234 
Ser70 
Lys73 
Ser130 
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Figure 13. Binding of Carboxylated Product in Active Site. Crystal structure of a mixture of carboxylated and decarboxylated 6-
APA-Ru products bound in the CTX-M-14 E166A mutant active site. Two conformations are observed for Ser70 and Lys73, reflecting 
the mixture of products in the active site. When the carboxylated product is present, Ser70 and Lys73 adopt the conformations colored 
in green. When the decarboxylated product is present, Ser70 and Lys73 adopt the conformations colored in cyan. The carboxylated and 
decarboxylated products bind identically in the active site and are colored in yellow, while the carboxylate group present on the 
carboxylated product is colored in green. 
Ser70 
Lys73 Ser130 
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Figure 14. Comparison of 1.18, 0.85, and 1.30 Å Structures.  The 1.18 and 0.85 Å structures of the decarboxylated 6-APA-Ru 
product in complex with CTX-M are shown aligned with the 1.30 Å structure capturing a mixture of the carboxylated and 
decarboxylated products. The 1.18 Å structure is colored light pink, the 0.85 Å structure is colored magenta, and the 1.30 Å structure is 
colored cyan. Conformations adopted when the carboxylated product is present are colored in green. When the decarboxylated product 
binds, Ser70 and Lys73 only adopt one conformation, and this conformation is consistent among all three structures. When the 
carboxylated product binds, Ser70 and Lys73 adopt a conformation not seen in the 1.18 and 0.85 Å decarboxylated product structures. 
Ser130 
Ser70 
Lys73 
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Figure 15. Movement of Ser70. Ser70 adopts the conformation in green when the carboxylated product is present, and the conformation 
in cyan when the decarboxylated product is present. Ser70 is forced up and away from the carboxylate group to relieve steric clashing. In 
the decarboxylated conformation Ser70 would be ~2.0 Å away from the carboxylate group, while in the carboxylated conformation 
Ser70 is ~3.5 Å away from the carboxylate group. It is likely that the conformation of Ser70 when the carboxylated product is present is 
energetically unfavorable, thus aiding in expelling the carboxylated product from the active site. Black lines indicate distances of Ser70 
conformations from the carboxylate group. 
Ser70 
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Figure 16. Synthesis of Compound 1. The synthetic approach for the preparation of compound 1. The reaction combines 6-
APA with 4-oxo-4-(ruthenocenyl) butanoic N-succinimidyl ester (active ester) to generate 6-APA-Ru. 
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Figure 17. 1H NMR of Compound 1. A-F shows the 1H NMR spectra of compound 1. 
a) 
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b) 
Figure 17. (Continued) 
	   59	  
  
c) 
Figure 17. (Continued) 
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d) 
Figure 17. (Continued) 
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e) 
Figure 17. (Continued) 
	   62	  
  
f) 
Figure 17. (Continued) 
	   63	  
  
Microorganism MIC (µg/mL) 
6-APA-Fe 1 
 
Ampicillin 6-APA 
 
Staphylococcus aureus subsp. 
aureus ATCC® 29213™ 
(MSSA) 
10 2 0.5 200 
Staphylococcus aureus subsp. 
aureus ATCC® 43300TM 
(MRSA) 
160 256 10 1600 
Staphylococcus epidermidis 
ATCC® 12228™ 
10 4 5 400 
Enterococcus faecalis ATCC® 
29212TM 
- 16 10 N.D. 
Clinical strains: methicillin  
sensitive Staphylococcus aureus 
30/11 - 4 
26/11 - 2 
1255/11 - 8 
1637(1)/11 - 0.5 
1730/11 - 4 
1826/11 - 2 
1863/11 - 2 
1933/11 - 4 
2187/11 (37) - 2 
2271/11 (41) - 2 
57/12 (47) - 4 
12/10 - 0.5 
Table 1. In vitro Antibacterial Activity of Compound 1 and 6-APA-Fe Compounds. 
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Data Collection  
Space Group P21
Cell Dimensions
      a, b, c (Å) 44.9, 106.8, 47.9
      !, ", # (°) 90.0, 101.9, 90.0
Resolution (Å) 50.00 - 1.18 (1.20-1.18)
No. Reflections 141750 (6158)
Rmerge (%) 5.4 (28.9)
I / óI 16.54 (3.15)
Completeness (%) 98.3 (85.9)
Redundancy 3.5
Refinement
resolution (Å) 46.92-1.18
Rwork/Rfree (%) 12.5/15.3
no. heavy atoms
     protein/ligand/water 4474/146/601
B-factors (Å2)
     protein/ligand/water 8.76/10.73/23.28
rms deviations
     bond lengths (Å) 0.008
bond angles (°) 1.38
  ramanchandran plot 
       most favored region(%) 91.3
      additionally allowed (%) 7.8
        generously allowed (%) 0.9
           * Values in parentheses represent highest resolution shells
Table 2. X-ray Data Collection and Refinement Statistics. 
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Chapter 3: 
 
Novel Penicillin Binding Protein Drug Discovery 
 
Overview 
 The emergence and rapid proliferation of antibiotic resistant bacteria in the past several 
decades has placed increased urgency on the development of new antibiotics and highlighted the 
need for new antibiotic targets. The PBPs are the targets of the β-lactam antibiotics, and 
represent attractive targets for new drug design due to their essential function in bacterial 
survival, accessibility, and lack of human homologs.98 In an effort to identify and develop new 
inhibitors against PBPs, a fragment based molecular docking approach was used to virtually 
screen compounds against three different PBP targets: S. aureus monofunctional 
transglycosylase, P. aeruginosa PBP5, and P. aeruginosa PBP1a. Each target was successfully 
purified and crystallized, and an activity assay was developed for each that allowed for the 
testing of compounds selected from docking runs. 
 
Introduction 
 
Bacterial Cell Wall Synthesis 
 The bacterial cell wall is a cross-linked peptidoglycan layer that is essential for cell 
survival, as it provides strength and rigidity to the cell wall, and protects the bacteria from 
osmotic shock.99,100 The monomer that composes the peptidoglycan layer is comprised of N-
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acetyl-glucosamine and N-acetyl-muramic-acid linked together into a disaccharide with a 
pentapeptide attached to the NAM portion.44,101 The NAG-NAM unit is synthesized in the 
cytoplasm as Lipid II and then transported across the cytoplasmic membrane,44,102 and once on 
the exterior of the cytoplasmic membrane, it undergoes the final steps of peptidoglycan 
formation. First, the monomers are linked together to form a glycan chain via a 
transglycosylation reaction, and then a transpeptidation reaction cross-links the peptide portion 
of the growing glycan chain, forming the net-like bacterial cell wall (Figure 18).44 The 
transglycosylation and transpeptidation steps are carried out by either HMM PBPs that contain 
both a transglycosylase and transpeptidase domain, or LMM PBPs comprised of only one of the 
domains.42-44,103 The β-lactam antibiotics have successfully inhibited the PBPs for decades as 
potent transpeptidase inhibitors, but the only known transglycosylase inhibitor, moenomycin, is 
unsuitable for human use.98,104,105 
 
 PBP Docking Targets 
 
  Staphylococcus aureus Monofunctional Transglycosylase 
 There are three enzymes which contain transglycosylase domains in S. aureus; 1) PBP2, 
a HMM PBP containing both a transglycosylase and transpeptidase domain; 2) MTG, a 
monofunctional enzyme containing only the transglycosylase domain; and 3) StgA, a largely 
uncharacterized enzyme containing only a transglycosylase domain as well.106 In the absence of 
PBP2 transglycosylase activity, MTG activity is essential for bacterial cell survival, while StgA 
is not, and this suggests that both PBP2 and MTG will need to be inhibited for any potential 
transglycosylase inhibitor to be effective.106 Fortunately, the structures of both S. aureus PBP2107 
	   67	  
and MTG98,108 have been determined, with the active sites of PBP2 and MTG found to be nearly 
identical.98,107,108 The structures show that when PBP2 and MTG bind to moenomycin, the only 
known transglycosylase inhibitor, they do so in a very similar fashion, leading to the conclusion 
that any potential inhibitors that bind to MTG will also very likely bind to PBP2. As a target for 
new drug design, MTG is more attractive than PBP2 as its smaller size (~24 KD vs. ~152 KD) 
should make it easier to manipulate experimentally, purify, and crystallize. This is partially 
demonstrated by the higher resolution of the MTG crystal structure (2.1 Å) vs. that of PBP2 (2.8 
Å).98,107 The smaller size of MTG also makes it more desirable than transglycosylase domains 
from PBPs found in other bacteria.98,109,110 
 
   MTG Transglycosylation Mechanism 
 Despite the importance of the transglycosylation reaction to cell wall formation, the 
actual mechanism of this reaction is still poorly understood. The current proposed 
transglycosylation mechanism begins with the binding of a Lipid II substrate to both the glycosyl 
acceptor and glycosyl donor site (Figure 19).98,107,108 The NAG 4-OH of the Lipid II in the 
glycosyl acceptor site is then deprotonated by Glu100 (Glu114 in PBP2) and simultaneously 
interacts with the C1 in the NAM subunit of Lipid II in the glycosyl donor site.98,107,108 At the 
same time, the pyrophosphate group of the glycosyl donor Lipid II leaves through a reaction 
which is proposed to be catalyzed by Glu156 and a divalent metal ion (commonly Mg2+ or 
Mn2+).98,107 However, an alternative proposal suggests that Lys140 and Arg148, not Glu156, may 
be essential for the leaving of the pyrophosphate group.108 As the pyrophosphate group leaves, a 
β-1,4 linkage is formed between the NAM subunit of Lipid II in the glycosyl donor site, and the 
NAG subunit of Lipid II in the glycosyl acceptor site, with the Lipid II in the glycosyl donor site 
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serving as the beginning of the growing glycan chain.98,107,108 At this point, the newly formed 
Lipid IV is transferred to the glycosyl donor site, and a new Lipid II substrate binds to the 
glycosyl acceptor site, beginning the cycle again and continuing the growth of the glycan 
chain.98,107,108 
 
   Moenomycin and Insights into Ligand Binding 
 To date, the only known inhibitor of transglycosylase activity is moenomycin (Figure 
20), and the vast majority of knowledge about ligand binding by transglycosylase comes from 
structures of moenomycin bound to various transglycosylases.98,107,111,112 Moenomycin was first 
discovered in 1965, and several other moenomycin-like natural products were discovered by the 
end of the 1970’s.111 Moenomycin has been found to be more potent than vancomycin,113 one of 
the most powerful “drugs of last resort”, but is unable to be used clinically due to poor 
pharmacokinetic properties.98,111,114 Instead, moenomycin has been used for decades as a growth 
promoter in animal feed, and even with its widespread use, there have been no reports of 
significant bacterial resistance to moenomycin.115  
However, a recent study has shown that resistance to moenomycin can be induced by 
mutations to residues in the transglycosylase active site.116 Specifically, it was shown that 
mutations to Tyr196 and Pro234 in S. aureus PBP2 and MTG resulted in resistance to 
moenomycin.116 The mutated residues are located in the general area of the active site and do not 
actually contact moenomycin, but may interact with it through nonspecific interactions.116 The 
mutation of Tyr196 and Pro234 also altered the ability of PBP2 and MTG to polymerize Lipid II, 
with the mutant proteins producing abnormally short polymer products, which ultimately lead to 
cell wall defects.116 The mutant proteins appear to have a reduced binding affinity for the 
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growing polymer chain, which leads to an increased probability of early product release, and 
results in the production of shorter than normal glycan chains.116 This reduced binding affinity 
for Lipid II also results in a reduced binding affinity for moenomycin, and the lower level of 
moenomycin binding is how resistance is likely conferred.116 
 Moenomycin has been found to bind in the glycosyl acceptor site,98,107,108 and how 
transglycosylase (MTG and PBP2 specifically) interacts with moenomycin provides clues as to 
what residues are key for ligand binding. When comparing the active sites of MTG and PBP2 
from previously solved crystal structures, the binding pose of moenomycin is strikingly similar, 
as are the active sites themselves, leading to the belief that potential inhibitors will bind to MTG 
and PBP2 in the same fashion (Figure 21). Previous studies have shown that mutation of the 
catalytic Glu100 residue abolishes MTG activity, as will mutations to both Lys140 and 
Arg148.98,108 Residues Asn141, Val223, Asn224, and Ser237 in MTG have also been shown to 
form direct hydrogen bonds with moenomycin, and may be critical for its binding; but what 
effect changes to these residues have on ligand binding has not been explored.98 These residues 
may serve as potential “hot spots” to target during drug design efforts. 
 
  Pseudomonas aeruginosa PBP5 
 PBP5 is a LMM PBP and one of the most abundant PBPs found in P. aeruginosa, which 
is an opportunistic pathogen that has been shown to exhibit high levels of antibiotic 
resistance.51,117-120 PBP5 functions as a DD-carboxypeptidase and regulates the degree of cross-
linking during bacterial cell wall formation by hydrolytically shortening the peptide stem of the 
newly forming peptidoglycan.51,121 This shortening may play a role in maintaining cell 
morphology, as has been seen in the functionally similar Escherichia coli PBP5.51,122,123 Like 
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other PBPs, PBP5 activity is inhibited by the β-lactam antibiotics through a mechanism, as noted 
in the previous chapter, extremely similar to that of the serine β-lactamases, with a catalytic 
serine residue catalyzing the formation of an acyl-enzyme complex with the β-lactam substrate 
(Figure 5). However, PBPs can only catalyze the acylation portion of this reaction, and lack the 
residue needed to effectively catalyze the deacylation of the acyl-enzyme complex and 
subsequently remove the hydrolyzed product from the active site. This results in the covalently 
linked acylation product remaining in the active site, rendering the PBP inactive.  
 PBP5 presents an attractive target for new drug discovery due to its importance in 
maintaining cell morphology and the structural similarities it shares with other PBPs. 
Interestingly, PBP5 has a low level of β-lactamase activity, and increased bacterial resistance to 
the β-lactam antibiotics due to its high expression level in vivo.51,124-126 This feature of PBP5 
presents a unique opportunity for inhibitor screening, because many biochemical assays are 
readily available for β-lactamase activity, but much less so for transpeptidase and DD-
carboxypeptidase activity. With the mechanism of PBP inhibition well known, the residues 
involved in the mechanism can be targeted during docking experiments to maximize the chances 
of identifying new inhibitors. 
 
  Pseudomonas aeruginosa PBP1a 
 PBP1a is a HMM PBP that catalyzes both the transglycosylation and transpeptidation 
steps of bacterial cell wall synthesis, and its function is essential in P. aeruginosa.127 PBP1a is 
still relatively unstudied, as it was not able to be successfully crystallized until 2014.127 
Crystallization of PBP1a showed that the active site is very similar to other transpeptidases and 
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the serine β-lactamases.127 The essential nature of PBP1a, along with structural knowledge of the 
active site, makes it an excellent target for docking experiments and new drug discovery. 
 
Results and Discussion 
 
 Monofunctional Transglycosylase 
  A critical part of the structure based drug design process is the ability to crystallize a 
protein of interest in order to study the interactions the binding site has with selected compounds. 
Although it was expected that MTG would be fairly easy to purify and crystallize based upon its 
small size, this was not the case. While MTG was successfully purified and crystallized, both 
efforts proved extremely challenging. Fragment based molecular docking against MTG was done 
using a previously published MTG structure (PDB 3HZS). 
 
  Protein Purification 
 The successful purification of MTG proved to be a challenging process, but was 
successfully completed. Two versions of MTG were purified, the wild type MTG, and an E100Q 
mutant that was shown in the literature to improve the crystallization of the protein but also 
rendered it catalytically inactive.98 The main issue faced with MTG purification was the inability 
to separate MTG from several contaminant proteins that were lowering the overall homogeneity 
of the sample, and low sample homogeneity results in decreased crystallization potential. Initial 
attempts to purify MTG focused on repeating and optimizing the published conditions, but these 
efforts were ultimately unsuccessful. Purification of MTG was then attempted by trying to use 
three columns in succession: a nickel-affinity column, followed by an anion-exchange column, 
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and finally a size exclusion column. While using all three columns in a row did improve the 
overall purity of MTG, the contaminant proteins were still present in the final sample. 
 Multiple other techniques were attempted such as AmSO4 precipitation, changes to the 
elution strategy, the use of different additives in the purification buffers, and altering the buffer 
pH; but all were ultimately unsuccessful at removing the contaminant proteins. The key to the 
successful purification of MTG ended up being the removal of the His-Tag from MTG after the 
use of a nickel-affinity column. The removal of the His-Tag allowed for the repeatable recovery 
of > 95% pure MTG WT and MTG E100Q, in quantitates which were suitable for crystallization 
experiments. The identity of the contaminant proteins was never accomplished, and it is believed 
that these contaminants were having some non-specific interactions with the His-Tag. The His-
Tag then “dragged” these contaminants with it through every step of the purification. This would 
explain why the proteins were unable to be removed until the cleavage of the His-Tag from 
MTG. 
 
  Protein Crystallization 
 Crystallization experiments were attempted with MTG E100Q throughout the process of 
identifying a successful purification strategy. As the E100Q mutation was reported to improve 
crystallization of the protein, E100Q would be used to identify crystallization conditions, and 
then the WT crystals would be grown using the identified conditions. Initial crystallization 
experiments used samples of MTG that had the contaminant proteins present, and despite setting 
up hundreds of screening drops at various temperatures, and using numerous different buffers 
and additives, crystals were not obtained. The screening with the impure MTG did not even 
reveal any lead conditions (conditions that form precursors to crystals) that could be optimized to 
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form crystals, and mostly precipitated out when screening, despite trying various concentrations 
of the protein. Attempts to crystallize MTG using the published conditions also failed. 
 Upon determination of a successful MTG purification strategy, and purification of > 95% 
pure MTG, crystallization efforts with E100Q improved almost immediately. The screening 
drops were found to contain much less precipitation, and several lead conditions were identified. 
Successful crystallization of MTG was finally accomplished when screening the protein at 4° C. 
Initial MTG crystals formed in clusters, and were too small and of insufficient quality for 
diffraction experiments. Through the use of crystal seeding, large plate-like MTG crystals were 
formed, and the crystals were found to diffract to ~4 Å (Figure 22). Attempts to repeat the 
crystallization condition at 20° C were unsuccessful, and crystals grown at 4° C did not survive 
being transferred to 20° C. MTG WT was successfully crystallized using the condition at 4° C, 
but the resulting crystals were of lesser quality than the E100Q crystals. Further crystallization 
and optimization efforts are ongoing to improve the resolution of current crystals, and identify 
new crystallization conditions.  
 
Virtual Screening 
 The program DOCK was used to screen the ZINC database’s fragment and lead-like 
subsets against a previously published (PDB 3HZS)98 MTG WT structure. Specifically, the 
glycosyl acceptor site was targeted for screening because this site has well defined features, such 
as prominent hydrophilic and hydrophobic functional groups, that are ideal for small molecule 
binding. Approximately 3 million compounds were screened, and the top scoring compounds 
were visually inspected for favorable interactions with the active site. Specifically, compounds 
that formed interactions with Glu100, Lys140, and Arg148 were favored, as mutations to these 
	   74	  
residues are known to abolish MTG activity. Residues Asn141, Val223, Asn224, and Ser237 
were also targeted, as they are known to form direct hydrogen bonds with moenomycin,98 and 
therefore may be important for inhibitor binding. Overall, 16 compounds (see Appendix 4) were 
selected from docking results for inhibition testing. 
 
  Compound Testing 
 To test the inhibitory potential of compounds selected from docking, an activity assay 
was developed which utilizes Oregon Green 488 labeled Lipid II (Figure 23). The Oregon Green 
488 Lipid II itself is fluorescent, and when the Lipid II is polymerized by the activity of 
transglycosylase, the fluorescence of the Lipid II is lost due to quenching effects. Thus, when 
MTG is active, a loss of fluorescence is seen over time, and when an inhibitor is present, the 
fluorescence level remains relatively unchanged (Figure 24). The use of the fluorescent Oregon 
Green 488 label allowed for the reaction to be easily monitored using a microplate reader at 
496/520 nM wavelengths. 
 Initial testing focused on determining the optimum concentration of MTG required for 
inhibitor testing, and it was found that 2 µM MTG was the lowest concentration able to be used 
before a drop-off in MTG activity was observed. Substrate concentration was then varied and the 
Km of MTG for the Oregon Green 488 Lipid II was determined to be 40 µM. The 16 selected 
compounds were tested in concentrations up to 2 mM based upon their solubility in the reaction 
buffer, and the reaction was carried out using 35 µM Oregon Green 488 Lipid II and 2 µM MTG 
WT. None of the 16 selected compounds were found to show any measureable inhibition of 
MTG (Figure 25). 
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 Although none of the compounds selected from virtual screening showed any inhibition 
against MTG, the MTG active site still represents an attractive and viable target for new drug 
discovery. There are no known structures of transglycosylase in complex with small molecule 
inhibitors, as all current structures show transglycosylase in complex with moenomycin or Lipid 
II and Lipid II analogs. It is likely that more than 16 compounds will need to be tested before an 
inhibitor is identified. By changing parameters in the docking program, as well as targeting 
different areas of the overall binding pocket, new and varied compounds can be selected, which 
will increase the odds of finding an MTG inhibitor. Further docking experiments are currently 
ongoing. 
 
 PBP5 
A previous study by our lab successfully purified and crystallized PBP5 (PDB 4K91),51 
with the crystals regularly diffracting to 1.8-2.1 Å. However, these crystals were unsuitable for 
use in the structure based drug design process because of how the proteins packed together 
during crystal formation. In the crystal, a tryptophan residue from an adjacent PBP5 monomer 
obstructs the active site (Figure 26). This meant that although a structure of PBP5 was available 
to dock to, complex structures of PBP5 and potential inhibitors would not be attainable, and it 
would be impossible to gain valuable information about how the inhibitors and the active site 
residues interacted. 
 
 Design of a New PBP5 Construct 
A new PBP5 construct was designed with the purpose of unobstructing the active site so 
determination of complex structures with potential inhibitors would be possible. To do this, a 
	   76	  
construct was designed that removed the relatively disordered C-Terminal domain of PBP5. It 
was hoped that removing the C-Terminal domain (~100 residues) would allow the protein to 
pack differently when forming crystals, and leave the active site unobstructed. It was also hoped 
that mutating the tryptophan residue that was obstructing the active site would not be necessary, 
but this remained an option in case removing the C-Terminal domain did not produce the desired 
results. Once designed, the gene for the new construct was synthesized commercially by DNA 
2.0. 
 
 Protein Purification 
Purification of the new PBP5 construct proceeded rapidly and a successful protocol was 
determined on the first attempt. Purification was accomplished through two steps: the sample 
was first run through a nickel-affinity column, and then through a size exclusion column, after 
which pure PBP5 was obtained. The amount of PBP5 attained during purification is quite high, 
with a typical purification yielding > 100 mg of protein. After purification, the purified protein 
was then used in crystallization experiments. 
 
  Protein Crystallization 
 Purified PBP5 at two different concentrations was screened against over 1000 
crystallization conditions at 20° C. Sixteen conditions were found to form crystals within five 
days of screening, with several other conditions forming crystals between 10 and 14 days after 
screening. The conditions for the best crystals were scaled up, and these conditions produced 
large, well formed, diffraction quality crystals within 1-2 days (Figure 27). These crystals were 
then crushed, and used as seeds in an attempt to further improve crystal quality. When using 
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seeds, PBP5 crystals grew at an incredibly fast rate, with diffraction quality crystals forming 
within 1-2 hours. 
 While seeding allowed for diffraction quality crystals to be obtained in only a few hours, 
an issue arose when attempting to cryo-cool the crystals for use in diffraction experiments. Cryo-
cooling is the process of flash freezing a crystal suspended in its crystallization condition for use 
in diffraction experiments. A cryo-protectant is usually added to the crystal drop to prevent the 
formation of white, unclear, ice during the flash freezing process, and to preserve the integrity of 
the crystal. Glycerol, sucrose, and low molecular weight PEG, are the most commonly used 
cryo-protectants. The addition of cryo-protectant to the crystal drop caused the PBP5 crystals to 
crack and shatter almost immediately. Tests were done using many of the most common cryo-
protectants but all caused the crystals to shatter upon being added to the drop.  
This cryo-cooling issue was overcome by adding a low amount of the cryo-protectant to 
the crystallization condition before crystals actually formed. An experiment was carried out 
where 1, 5, and 10% glycerol was added to the crystallization buffer, and drops set up in an 
attempt to grow crystals in the presence of glycerol. It was hoped that by actually growing in the 
presence of glycerol, formed crystals would not shatter upon the addition of a higher 
concentration (usually 20-30%) of glycerol for use as a cryo-protectant. PBP5 crystals grew 
successfully at each concentration of glycerol, and were slightly larger than crystals grown 
without glycerol present. It was also found that none of the crystals shattered upon the addition 
of 30% glycerol for use as a cryo-protectant. This showed that growing the crystals in the 
presence of even 1% glycerol would allow them to tolerate the addition of higher concentrations 
of glycerol. With the cryo-protectant issue solved, PBP5 crystals were successfully cryo-cooled 
for use in diffraction experiments. 
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 Structure Determination 
 Diffraction experiments using PBP5 crystals were carried out using the SER-CAT 22-
BM beamline at the Advanced Photon Source, Argonne National Laboratory. The best crystal 
diffracted to 2.64 Å, which was lower than the resolution of the original PBP5 crystals with the 
obstructed active site. However, based on ample previous experience, the beamline used was 
known to commonly give resolutions ~0.5-0.6 Å below a crystals diffraction capability. SER-
CAT possesses a second beamline, 22-ID, which almost always yields much higher resolution 
data. A 0.5-0.6 Å increase in resolution would bring the resolution of the new PBP5 crystals in 
line with the resolution obtained using the old PBP5 crystals, so the 2.64 Å dataset was regarded 
as a satisfying result. The SER-CAT 22-ID beamline will be used in future PBP5 diffraction 
experiments to confirm the expected increase in resolution. 
 The previously published PBP5 structure (PDB 4K91)51 from the literature was used as a 
template to aid in phase determination for the new PBP5 dataset, and the structure for the new 
PBP5 construct was successfully solved. Upon examining the structure, it could be seen that the 
removal of the C-Terminal domain had produced the desired result of the protein packing 
differently during crystal formation. This resulted in the PBP5 active site being unobstructed 
when the crystal formed (Figure 28), which would allow potential inhibitors to bind in the active 
site. Ultimately, the design of the new PBP5 construct was a major success and will allow for the 
determination of structures in complex with potential inhibitors, thus aiding in structure based 
drug design against PBP5. 
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  Virtual Screening 
 Fragment based molecular docking was carried out against PBP5 by docking the ZINC 
fragment and lead-like subsets into the now unobstructed active site. The similarity of the PBP5 
active site (Figure 10) and mechanism to the serine β-lactamases guided docking efforts, and an 
area near the catalytic serine, Ser41 in PBP5, was targeted. Docking runs are still being carried 
out, with compounds to be selected for inhibitor testing in the near future. 
 
  Compound Testing 
 As compounds from virtual screening have not yet been selected, inhibition testing has 
not yet taken place. However, an assay has been identified which will allow for the future 
identification of PBP5 inhibitors. Previous studies have shown that P. aeruginosa PBP5 has a 
low level of β-lactamase activity and, as a consequence, causes some level of natural resistance 
to the β-lactams.51,124-126 The β-lactamase activity of PBP5, while low, allows for a routinely 
used β-lactamase activity assay to be adapted as a PBP5 inhibition assay. 
 The inhibition assay will make use of the β-lactam, nitrocefin (Figure 29). Nitrocefin is a 
chromogenic cephalosporin β-lactam, which changes color from yellow to red when the amide 
bond in the β-lactam ring is hydrolyzed through the activity of β-lactamase.128 The color change 
is quite profound, and can be easily seen with the naked eye (Figure 30). Quantification of this 
color change can be determined by measuring the change in absorbance of the reaction mixture 
over time using a microplate reader. By measuring the change in absorbance over time, 
compounds selected from virtual screening can be tested for their inhibitory properties against 
PBP5. 
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 Early tests using PBP5 in the nitrocefin assay have been successful, with PBP5’s β-
lactamase activity being sufficient to induce a full yellow to red color change in the reaction 
solution. However, PBP5’s weak β-lactamase activity means the reaction proceeds at fairly slow 
rate, with PBP5 taking about 40 minutes to induce a full yellow to red color change (for 
comparison, CTX-M β-lactamase induces the full color change in a matter of minutes). This 
means that the reaction will need to be monitored for a longer period of time than is standard 
when testing actual β-lactamases. Further optimization of the assay will need to be carried out, 
but the successful test of PBP5 demonstrates that the nitrocefin assay should be effective at 
identifying inhibitors from virtual screening compounds. 
 
 PBP1a 
 There was little information about P. aeruginosa PBP1a in the literature, and its structure 
was only recently determined (PDB 4OON).127 Purification of PBP1a was reported to be 
challenging, with the protein needing controlled proteolysis with trypsin, leading to the 
subsequent loss of the transglycosylase domain, for purification to be successful.127 However, its 
essential function in P. aeruginosa makes PBP1a an attractive target for new drug discovery 
directly targeting the transpeptidase domain. 
   
Protein Purification 
 Only the transpeptidase domain of PBP1a was cloned for purification and crystallization, 
as the expectation was that it might lead to better crystals than the larger and more flexible full-
length protein. As expected, purification of PBP1a proved to be challenging, with multiple 
attempts made before a successful strategy was determined. The main issue was with the 
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solubility of the protein throughout the purification, as in early attempts PBP1a precipitated 
badly from solution, and still slightly precipitates from solution even after successful 
purification. Purification of PBP1a proceeds through a four-step process: 1) initial use of a 
nickel-affinity column; 2) cleavage of the His-Tag with TEV; 3) rerunning through a nickel-
affinity column; 4) use of a gel filtration column. Initially, an ion exchange column was also 
used, but overall recovery and purity of PBP1a suffered, so it was removed from the final 
strategy. The four-step protocol allowed for the repeatable purification of PBP1a, but minor 
precipitation still occurs and centrifugation of the sample is required after each step in order to 
remove any precipitation. It should also be noted that, unlike the purification strategy for PBP1a 
in the literature, this PBP1a purification strategy does not require controlled proteolysis and can 
be regarded as an improvement over the literature purification strategy.  
 
  Protein Crystallization 
 Purified PBP1a protein was used in crystallization experiments at several concentrations, 
and screened against over 1000 crystallization conditions at 20° C. One day after setting up 
screens, 28 conditions were found in which PBP1a crystallized, with an additional 10 conditions 
producing crystals after four days. Three different crystal forms were found within the 38 hits: 1) 
thick five and six-sided crystals (Figure 31a), 2) elongated hexagonal crystals (Figure 31b), and 
3) thin rectangular crystals (Figure 31c). The five and six-sided crystals, and elongated 
hexagonal crystals were outliers in that they were only found in one condition each, with the 
other 36 conditions producing varying degrees of thin rectangular crystals. 
 Efforts were first focused on the two conditions that did not produce rectangular crystals, 
as those crystals appeared to be the best formed. The condition that grew the thick five and six-
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sided crystals was unable to be scaled up, although attempts to accomplish this are still 
underway. The condition that grew the elongated hexagonal crystals was able to be successfully 
scaled up, and produced crystals after four days. Large, diffraction quality, crystals were 
eventually obtained by altering the concentration of protein in the crystal drop, and through the 
use of crystal seeding techniques. The resolution of these crystals is currently unknown as 
diffraction experiments with them have yet to be conducted.  
After attempting to scale up the outlier conditions, efforts were focused on the remaining 
conditions. The condition that produced the best looking rectangular crystals was successfully 
scaled up and formed crystals within 1-2 days. However, upon scaling up the crystals are still 
quite thin, and this is not optimal for diffraction experiments, as thicker crystals tend to yield 
better data. Optimization efforts to increase the thickness and quality of the rectangular crystals 
are currently underway. 
 
Virtual Screening 
 Molecular docking experiments have just recently started to be conducted against PBP1a 
by docking the fragment and lead-like subsets from the ZINC database against the structure of 
PBP1a from the literature (PDB 4OON).127 The docking strategy is similar to that of PBP5, in 
that the area of the catalytic serine residue, Ser461 in PBP1a, will be targeted. The structure from 
the literature will be used for docking until a PBP1a structure can be solved from one of the three 
obtained crystal forms. No compounds have currently been selected for inhibition testing, 
although compounds are planned to be tested in the near future as more docking runs are 
completed. 
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  Compound Testing 
Transpeptidase activity is relatively challenging to assay biochemically. The nitrocefin 
assay, as previously discussed for PBP5 and β-lactamases, will be adapted for screening 
compounds against PBP1a. Although PBP1a cannot hydrolyze nitrocefin, the formation of the 
acyl-enzyme complex opens up the β-lactam ring and leads to color change in the substrate.  
Although the reaction is irreversible and the ‘substrate’ is not turned over, the reaction can be 
monitored by using a relatively large amount of enzyme and substrate, and measurements taken 
before all the enzyme molecules become covalently linked to nitrocefin. 
 
Conclusions 
 Structure based drug design was carried out against three different PBP targets in order to 
identify novel PBP inhibitors. All three targets were successfully purified and crystallized, and 
an activity assay developed for each. Further optimization of current crystallization conditions, 
as well as screening to identify new conditions, is currently underway for each target. A 
fragment based molecular docking method was used to virtually screen the fragment and lead-
like subsets of the ZINC database against the active site of all three targets. Although no novel 
inhibitors were identified, further rounds of virtual screening are currently being conducted, and 
inhibitors are expected to be identified against all three targets. 
 
 
 
 
 
	   84	  
Experimental Procedures 
 
 Monofunctional Transglycosylase 
 
  Protein Purification 
  The MTG gene, either E100Q or WT, was cloned into a pET15-MHL plasmid vector, 
and then transformed into E. coli BL21-(DE3)-Ripl cells. E. coli was cultured in 2XYT broth 
containing 50 µg/ml ampicillin, 50 µg/ml chloramphenicol, 200 mM betaine, and 5 mM sorbital, 
at 37° C with shaking at 225 rpm, until the OD600 reached 0.6-0.8. Cells were harvested by 
centrifugation at 4000 rpm, for 30 min, at 4° C. The pellet was resuspended in M9 Minimal 
Media containing 50 µg/ml ampicillin, 50 µg/ml chloramphenicol, and 22.2 mM glucose. 
Overexpression of the MTG protein was induced with 5 mM IPTG at room temperature, with 
shaking at 225 rpm, overnight. Cells were then harvested by centrifugation at 4000 rpm, for 30 
min, at 4° C. The pellet was resuspended in Buffer A (25 mM Tris pH 8.0, 500 mM NaCl, 0.5% 
CHAPS) and a protease inhibitor tablet was crushed and dissolved in the resuspension. The 
resuspended cells were lysed by sonication using a program of 30 sec ON and 60 sec OFF at 
amplitude 10, for a total of 5 min. Cell lysate was cleared by ultra-centrifugation at 35,000 rpm, 
for 30 min, at 4° C. The lysate was then filtered, and brought to a concentration of 50 mM 
Imidazole.  
The protein sample was loaded onto a 5 ml HisTrapHP nickel-affinity column at 0.4 
ml/min using an AKTA Explorer 100 system. After loading, the column was washed with 10% 
Buffer B (25 mM Tris pH 8.0, 500 mM NaCl, 0.5% CHAPS, 500 mM Imidazole) at 0.5 ml/min 
until the UV280 reading baselined. Protein was eluted from the column in one large peak using 
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100% Buffer B, and peak fractions pooled. The His-Tag was cleaved off MTG by adding TEV 
protease in a 1:10 ratio by weight (TEV mg:MTG mg) to the pooled fractions, and brining the 
solution to a final concentration of 5 mM BME and 20% glycerol. The reaction was allowed to 
proceed for 2.5-3 hours at room temperature, then 4° C overnight. After overnight incubation, 
the reaction was diluted with Buffer A so that the final imidazole concentration was < 10 mM, 
and then loaded onto a 5 ml HisTrapHP nickel-affinity column at 0.5 ml/min. After loading, the 
column was washed with Buffer A until the UV280 baselined, and then the column was washed 
with 10% Buffer B. The flow-through and wash were collected, and MTG presence in the wash 
was confirmed by SDS-PAGE. The protein was concentrated to a volume < 500 µl, and then 
loaded onto a 24 ml SuperDex75 100/300 column, at a rate of 0.2 ml/min using Buffer A. The 
protein eluted after about 10 ml and its purity was confirmed by SDS-PAGE. MTG was 
concentrated, aliquoted, and then flash frozen.  
 
  Protein Crystallization 
 Before crystallization screening, thawed MTG E100Q aliquots were brought to 16.67% 
glycerol concentration. MTG E100Q was then screened against multiple crystallization screening 
kits from Qiagen (over 1000 conditions total), through the use of the Art Robbins Instruments 
Phoenix liquid-handling platform. Screening drops (0.4-0.8 µl volume) were set up in 1:1 and 
2:1 ratios (MTG:crystallization condition) using 10.37 mg/ml MTG E100Q. Crystallization 
screens were incubated at both 4° and 20° C, and checked daily for the next two weeks. After 
three days, multiple conditions at 4° C were found to produce small clusters of needle-like 
crystals. The condition that produced the best crystals was composed of 0.1 M CHES pH 9.5, 
and 20% (w/v) PEG 8000. This condition was successfully scaled up using larger drops (2-4 µl 
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volume) and clusters of needle crystals again grew after three days. The clusters were crushed 
thoroughly and used as seeds in order to increase crystal size and quality. 
 The seeds were diluted 1:100 and 1:1000 in the crystallization buffer, and then drops 
were set up using the seed dilutions and fresh protein. The use of seeds resulted in small, square, 
plate crystals forming after one day at 4° C. The small plate crystals were then crushed and used 
as seeds in the same manner as the original clusters of needle crystals. Using the small plate 
crystals as seeds resulted in the formation of much larger plate crystals after one day at 4° C. 
Further experiments using the large plate crystals as seeds failed to improve the crystal quality. 
MTG WT was crystallized using the same condition, but produced crystals of lesser quality than 
MTG E100Q. 
 
  X-Ray Data Collection and Structure Determination 
 X-ray diffraction data for MTG E100Q crystals were collected at the SER-CAT 22-BM 
beamline at the Advanced Photon Source (APS) at Argonne National Laboratory. Diffraction of 
the crystals was found to be poor, and no better than ~4 Å. HKL2000 was used to process the 
diffraction data.94 No structures were determined due to the low resolution of the data. 
 
  Virtual Screening 
 Virtual screening was performed using the program DOCK 3.5.54. The ZINC database 
fragment and lead-like subsets were docked into the PDB 3HZS98 active site. To prepare the 
structure for docking, all ions, ligands, and waters were removed. The program Dockblaster5c 
was used to generate matching spheres, with a total of 60 spheres used for each docking run. The 
grids used to score the binding poses were calculated by summing the energies calculated by 
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DISTMAP (excluded volume grid), CHEMGRID (VDW potential), and DelPhi (desolvation). 
Scored compounds were visually inspected using Pymol.  
 
Activity Assay 
 The reaction mixture was composed of 35 µM Oregon Green 488 Lipid II, 3.92 mM 
Tween-80, 25 mM HEPES pH 7.5, 15 mM MnCl2 and 2 µM MTG WT, with reagents added in 
the order presented. Potential inhibitors were added immediately before the addition of MTG, 
and at a concentration of up to 2 mM based upon their solubility in the reaction buffer. The 
reaction proceeded in individual wells of black 384 well microplates. The fluorescence level of 
the reaction was measured over time at 496/520 nM wavelengths, and at 25° C, using a BioTek 
Cytation 5 Microplate Reader. Readings were taken every 2.5 minutes for 30 minutes total. 
 
 PBP5 
 
  Protein Purification 
 The PBP5 gene was synthesized commercially by DNA 2.0, cloned into their proprietary 
pD441-NHT vector, and then transformed into BL21-Gold (DE3) E. coli cells for expression. 
Cells were cultured in LB broth containing 50 µg/ml kanamycin, at 37° C with shaking at 225 
rpm, until the OD600 reached 0.6-0.8. Overexpression of the PBP5 protein was induced with 5 
mM IPTG at room temperature, and with shaking at 225 rpm, overnight. Cells were then 
harvested by centrifugation at 4000 rpm, for 30 min, at 4° C. The pellet was resuspended in 
Buffer A (25 mM Tris pH 8.0, 500 mM NaCl) and a protease inhibitor tablet was crushed and 
dissolved in the resuspension. The resuspended cells were lysed by sonication using a program 
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of 30 sec ON and 60 sec OFF at amplitude 10, for a total of 5 min. Cell lysate was cleared by 
ultra-centrifugation at 35,000 rpm, for 30 min, at 4° C. The lysate was then filtered. 
 The protein sample was loaded onto a 5 ml HisTrapHP nickel-affinity column at 0.3 
ml/min using an AKTA Explorer 100 system. After loading, the column was washed with 10% 
Buffer B (25 mM Tris pH 8.0, 500 mM NaCl, 500 mM Imidazole) at 1.0-1.5 ml/min until the 
UV280 reading baselined. Protein was eluted from the column using an increasing concentration 
of Buffer B from 10-100% over 60 min, at 0.5 ml/min. Fractions were tested for presence of 
PBP5 by SDS-PAGE. The PBP5 containing fractions were then pooled and concentrated to 1.0 
ml for loading onto a 124 ml SuperDex75 16/60 gel filtration column. The sample was loaded 
onto the column, and then run at 0.5 ml/min using Buffer C (25 mM Tris pH 8.0, 150 mM NaCl). 
Eluted fractions were tested for purity by SDS-PAGE, and pure PBP5 fractions were pooled. The 
pooled fractions were concentrated, aliquoted, and then flash frozen. 
 
  Protein Crystallization 
 PBP5 was screened against multiple crystallization screening kits from Qiagen (over 
1000 conditions total), through the use of the Art Robbins Instruments Phoenix liquid-handling 
platform. Screening drops (0.4-0.8 µl volume) were set up in 1:1 and 2:1 ratios 
(PBP5:crystallization condition) using 12.79 and 22.16 mg/ml PBP5. Crystallization screens 
were incubated at 20° C, and checked daily for the next two weeks. Between 1-5 days after 
screening, 16 conditions were found to form crystals, with 3 additional conditions forming 
crystals between 10-14 days after screening. Over 100 conditions were found to produce phase 
separations and quasi-crystals. The condition that produced the best crystals was composed of 
0.2 M magnesium nitrate, and 20% (w/v) PEG 3350. This condition was successfully scaled up 
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using larger drops (2-4 µl volume) and cube-shaped crystals grew after 1-2 days. The crystals 
were crushed thoroughly and used as seeds in order to increase crystal size and quality. The 
seeds were diluted 1:100 and 1:1000 in the crystallization buffer, and then drops were set up 
using the seed dilutions and fresh protein. The use of seeds caused large, diffraction quality 
crystals to grow in 1-2 hrs. 
 In order to solve the cryo-cooling problem, 1, 5, and 10% glycerol was added to the 
crystallization condition (0.2 M magnesium nitrate, 20% (w/v) PEG 3350), and drops were set 
up. Cube-shaped PBP5 crystals formed in 2-3 days in all drops. Seeding was used to increase 
crystal size and quality, and resulted in large, diffraction quality crystals that resisted shattering 
when exposed to high concentrations of glycerol. Crystals were transferred to drops containing 
the crystallization condition and 30% glycerol, and then harvested and cryo-cooled using liquid 
nitrogen. 
 
  X-Ray Data Collection and Structure Determination 
 X-ray diffraction data for PBP5 crystals were collected at the SER-CAT 22-BM beamline 
at the Advanced Photon Source (APS) at Argonne National Laboratory. HKL2000 was used to 
process the diffraction data, and the highest resolution dataset was found to be 2.64 Å.94 A 
truncated version of the structure PDB 4K9151 was used as a template for phase determination. 
The CCP4 suite and COOT were used for structure refinement and model building.96,97 
 
Virtual Screening 
 Virtual screening was performed using the program DOCK 3.5.54. The ZINC database 
fragment and lead-like subsets were docked into the PBP5 active site. To prepare the structure 
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for docking, all ions and waters were removed. The program Dockblaster5c was used to generate 
matching spheres, with a total of 60 spheres used for each docking run. The grids used to score 
the binding poses were calculated by summing the energies calculated by DISTMAP (excluded 
volume grid), CHEMGRID (VDW potential), and DelPhi (desolvation). Scored compounds were 
visually inspected using Pymol. 
 
  Activity Assay 
 For initial testing and confirmation the nitrocefin assay would work with PBP5, 1 µl of 
100 mM nitrocefin was added to 1 µl of 12.79 mg/ml PBP5. A complete yellow to red color 
change was observed after 2-3 minutes. The test was then scaled up, and 1ml of 100 mM 
nitrocefin was added to 9 ml of 12.79 mg/ml PBP5, with a complete yellow to red color change 
observed after 40 minutes. Further testing is underway to find the optimal concentration of PBP5 
needed for the reaction. 
 Although PBP5 has not yet been tested in the full assay, a protocol for the assay has been 
developed. The reaction will proceed in a reaction buffer composed of 100 mM Tris pH 7.0, and 
0.02% Triton X100. 90 µl of the reaction buffer is added to 12 wells of a standard, clear-
bottomed microplate. A stock solution is made where 100 mM nitrocefin is diluted in the 
reaction buffer, so that the final nitrocefin concentration is 1 mM. Then, 90 µl of 1 mM 
nitrocefin is added to the last well of the microplate, and mixed. 90 µl from the mixed well is 
then taken, added to the preceding well, and mixed. This process is repeated for each well, with 
the 90 µl taken from the final well being discarded. This produces an increasing gradient of 
nitrocefin concentration from well 1 to 12 (low to high). An appropriate concentration (TBD) of 
PBP5 will be added to each well, and the plate inserted into a BioTek Cytation 5 Microplate 
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Reader that has been pre-warmed to 37° C. Compounds being tested will be added immediately 
before the addition of PBP5. The reaction will be monitored at 480 nm wavelength for an 
appropriate amount of time (TBD) with readings taken at appropriate intervals (TBD). Data will 
then be analyzed to determine if any of the compounds being tested inhibit PBP5 activity. 
 
PBP1a 
 
 Protein Purification 
 The PBP1a gene was cloned into a pET15-MHL vector and then transformed into E. coli 
BL21-Gold (DE3) cells for expression. Cells were cultured in LB broth containing 35 µg/ml 
chloramphenicol and 100 µg/ml ampicillin, at 37° C with shaking at 225 rpm, until the OD600 
reached 0.6-0.8. Overexpression of the PBP1a protein was induced with 5 mM IPTG at 17° C, 
and with shaking at 225 rpm, overnight. Cells were harvested by centrifugation at 5000g for 10 
min at 4° C. The pellet was resuspended in Buffer A (20 mM Tris pH 8.0, 300 mM NaCl, 10% 
(v/v) Glycerol, 20 mM Imidazole) and two protease inhibitor tablets were crushed and dissolved 
in the resuspension. The resuspended cells were lysed by sonication using a program of 10 sec 
ON and 15 sec OFF at amplitude 6, for a total of 15 min. Cell lysate was cleared by ultra-
centrifugation at 40,000 rpm, for 40 min, at 4° C. The lysate was then filtered. 
 The protein sample was loaded onto a 5 ml HisTrapHP nickel-affinity column at 1.0 
ml/min using an AKTA Explorer 100 system. After loading, the column was washed with Buffer 
A at 1-2 ml/min until the UV280 reading baselined. Protein was eluted from the column using an 
increasing concentration of Buffer B (20 mM Tris pH 8.0, 300 mM NaCl, 10% (v/v) Glycerol, 
500 mM Imidazole) from 0-100% over 200 min, at 1 ml/min. Fractions were tested for the 
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presence of PBP1a by SDS-PAGE. The PBP1a containing fractions were then pooled, and 
underwent buffer exchange with Buffer C (20 mM Tris pH 8.0, 150 mM NaCl, 10% (v/v) 
Glycerol) so that the final imidazole concentration was < 5%. TEV protease was added to the 
protein in a 1:10 ratio by weight (TEV mg:PBP1a mg) to cleave the His-Tag off PBP1a. The 
TEV cleavage reaction was allowed to proceed overnight at 4° C. 
 After running overnight, the reaction solution was filtered to remove any precipitation 
and then loaded onto a 5 ml HisTrapHP column at 0.5 ml/min. The column was then washed 
with Buffer A until the UV280 reading baselined. The flow-through and wash were collected and 
pooled, with PBP1a presence confirmed by SDS-PAGE. The protein was concentrated to 1.0 ml 
for loading onto a 124 ml SuperDex75 16/60 gel filtration column. The sample was loaded onto 
the column, and then run at 0.5 ml/min using Buffer D (20 mM Tris pH 8.0, 200 mM NaCl). 
Eluted fractions were tested for purity by SDS-PAGE, and pure PBP1a fractions pooled. The 
pooled fractions were concentrated, aliquoted, and flash frozen. 
 
  Protein Crystallization 
 PBP1a was screened against multiple crystallization screening kits from Qiagen (over 
1000 conditions total), through the use of the Art Robbins Instruments Phoenix liquid-handling 
platform. Screening drops (0.4-0.8 µl volume) were set up in 1:1 and 2:1 ratios 
(PBP1a:crystallization condition) using 7.7 and 8.9 mg/ml PBP1a. Crystallization screens were 
incubated at 20° C, and checked daily for the next two weeks. One day after setting up screens, 
28 conditions were found to form crystals, with an additional 10 conditions producing crystals 
after four days. Three main crystal forms were grown; thick five and six-sided crystals (1), 
elongated hexagonal crystals (2), and thin rectangular crystals (3). The crystallization conditions 
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that produced the best crystals for each form are: 1) 15% (w/v) PEG 6000, 5% (w/v) Glycerol, 2) 
0.1 M Tris pH 7.0, 50% (v/v) PEG 200, and 3) 0.2 M Sodium acetate, 20% (w/v) PEG 3350. 
Crystal forms 1 and 3 grew after one day, while form 2 grew after four days.  
The condition for crystal form 1 was unable to be scaled up into larger (2-4 µl volume) 
drops, but efforts to accomplish this are still underway. Condition 2 was able to be successfully 
scaled up, and again produced crystals after four days. The crystals were crushed thoroughly and 
used as seeds in order to increase crystal size and quality. The seeds were diluted 1:100 and 
1:1000 in the crystallization buffer, and then drops were set up using the seed dilutions and fresh 
protein. The use of seeds, and varying the protein concentration, caused large diffraction quality 
crystals to grow in 1-2 days. Diffraction experiments with crystals from condition 2 have yet to 
be conducted. Condition 3 was able to be successfully scaled up and produced crystals in 1-2 
days, however crystals were not of sufficient quality for diffraction experiments. 
 
  Virtual Screening 
 Virtual screening was performed using the program DOCK 3.5.54. The ZINC database 
fragment and lead-like subsets were docked into the PDB 4OON127 active site. To prepare the 
structure for docking, all ions and waters were removed. The program Dockblaster5c was used to 
generate matching spheres, with a total of 60 spheres used for each docking run. The grids used 
to score the binding poses were calculated by summing the energies calculated by DISTMAP 
(excluded volume grid), CHEMGRID (VDW potential), and DelPhi (desolvation). Scored 
compounds were visually inspected using Pymol. 
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  Activity Assay 
 The activity assay for PBP1a will be carried out in a similar fashion to the assay 
described for PBP5. It will utilize large amounts of PBP1a and nitrocefin to account for the fact 
that PBP1a cannot “turn over” nitrocefin and will irreversibly form an acyl-enzyme complex. 
The reaction will be monitored using a BioTek Cytation 5 Microplate Reader, with readings 
taken before all PBP1a becomes covalently linked to nitrocefin. The exact amount of PBP1a and 
nitrocefin needed, as well as the timing of the reaction, has yet to be determined. 
 
Note to Reader #1 
Figure 19 in this chapter was previously published108 by Huang, et al. PNAS 109, 6496-
6501, (2012), and used with permission (see Appendix 3). 
 
Note to Reader #2 
 The MTG activity assay described in this chapter was developed in collaboration with 
Larry Blaszczak of Muroplex Pharmaceuticals. Dr. Blaszczak was also responsible for the 
synthesis of Oregon Green 488 Lipid II. 
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Figure 18. Bacterial Cell Wall Synthesis. During cell wall formation, a 
transglycosylation reaction occurs where Lipid II monomers are linked together to 
form a growing glycan chain. A transpeptidation reaction then cross-links the 
peptide portion of the growing glycan chain, leading to the formation of the bacterial 
cell wall. β-lactam antibiotics inhibit the transpeptidation reaction. β-lactamases 
hydrolyze the β-lactam antibiotics and render them inactive. 
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Figure 19. Proposed Mechanism for Transglycosylation in MTG. A) Lipid II substrate binds to the glycosyl acceptor (S1) and 
glycosyl donor (S2) site. Both sites are shaded in red. B) E100 deprotonates the NAG 4-OH in the acceptor site and is followed by a 
simultaneous reaction with the C1 of Lipid II in the donor site, as K140 and R148 facilitate the leaving of the pyrophosphate group 
on the NAM in the donor site. C) A β-1,4 linkage forms between the Lipid II in the acceptor and donor sites. D) The newly formed 
Lipid IV is transferred from the acceptor site to the donor site, and becomes the beginning of the growing glycan chain. E) A new 
Lipid II binds in the empty acceptor site, and the cycle begins again.108  
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Figure 20. Structure of Moenomycin. Moenomycin is composed of six rings (labeled A-F) attached via 
a phosphoglycerate linkage to a long polyprenyl chain. 
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Figure 21. Moenomycin Binding to MTG and PBP2. 
Moenomycin adopts a nearly identical binding pose in the 
very similar MTG and PBP2 active sites. MTG is shown 
in white, and PBP2 is shown in yellow. The protein active 
sites are shown as sticks, while moenomycin is presented 
as balls and sticks. 
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Figure 22. Increase in MTG E100Q Crystal Size and Quality Through Seeding. a) Small 
needle clusters of MTG crystals initially obtained from screening experiments. b) Larger, better 
formed MTG crystals obtained by using seeds from crystals in panel a. c) Very large, well-
formed plate crystals obtained by using seeds from crystals in panel b. 
a) b) 
c) 
	   100	  
  
O
O
O
NHAc
OH
HO
OH
HO
O NHAc
O
HN
NH
O
HN
O
COO
O
H
H
P
O
O
O P
O
O
O
H
N
O
O
OH
F
O
F
HOOC
H
Figure 23. Structure of Oregon Green 488 Labeled Lipid II. The Oregon 
Green 488 fluorescence label (colored in green) is linked to the Lipid II 
substrate. 
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Figure 24. Loss of Fluorescence Over Time. The fluorescence of the Oregon Green 488 Lipid II is quenched 
when MTG is active and polymerizes Lipid II. As a result, the fluorescence level of the reaction decreases. When 
the catalytically inactive MTG E100Q mutant is used, Lipid II is not polymerized and fluorescence remains steady. 
Fluorescence also remains steady when MTG is not used in the reaction, when the MTG inhibitor moenomycin is 
present, and when a divalent metal ion is not present. If a compound selected for testing acts as a MTG inhibitor, no 
loss, or a reduced loss, of fluorescence would be expected. 
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Figure 25. Fluorescence in the Presence of Potential Inhibitors. The first six compounds tested showed 
no inhibition of MTG, as the fluorescence decreased steadily over time, indicating MTG was still actively 
polymerizing the Oregon Green 488 Lipid II substrate. Compounds were tested up to 2 mM concentration 
based upon their solubility in the reaction buffer. Data for compounds 7-16 is not shown, but all showed the 
same steady decrease in fluorescence as seen in the figure. 
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Figure 26. Obstructed PBP5 Active Site. In the previously determined PBP5 crystal, Trp73 from an adjacent PBP5 
monomer (blue) obstructs the active site. This would prevent the determination of complex structures showing potential 
inhibitors bound to PBP5. Ser41 is the catalytic residue in PBP5. 
Ser41 
Trp73 
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Figure 27. PBP5 Crystals. Large, cube-shaped, diffraction quality crystals of PBP5. 
Crystals pictured formed two days after drop set up. 
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Figure 28. Unobstructed PBP5 Active Site. In the crystal of the new PBP5 construct, different packing 
results in the adjacent monomer (blue) no longer obstructing the active site. This will allow for the 
determination of structures showing PBP5 in complex with potential inhibitors. 
Ser41 
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Figure 29. Structure of Nitrocefin. Nitrocefin is a chromogenic cephalosporin. The β-lactam ring is susceptible to 
hydrolysis by β-lactamases. 
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Figure 30. Nitrocefin Activity Assay. Upon hydrolysis 
of the β-lactam ring through β-lactamase activity, 
Nitrocefin undergoes a color change from yellow to 
red. This color change can be monitored over time to 
determine the presence or absence of β-lactamase 
activity. 
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Figure 31. PBP1a Crystal Forms. A-C show the different crystal forms of PBP1a. a) 
Thick, five and six-sided crystals. b) Elongated hexagonal crystals. c) Thin, rectangular 
crystals. 
a) 
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   b) 
Figure 31. (Continued) 
	   110	  
  c) 
Figure 31. (Continued) 
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Chapter 4: 
 
Inhibition of Slingshot Phosphatase 1 
 
Overview 
 The rapidly increasing number of people afflicted with Alzheimer’s disease has the 
potential to become a global health crisis, as no treatment for AD currently exists. The lack of an 
effective treatment may be due in part to the somewhat uncertain nature of the mechanism(s) 
behind AD symptoms. However, the defining characteristics of AD are the accumulation of the 
proteins Aβ and Tau in the brain.10,14-17 In an effort to develop a novel treatment for AD, a 
fragment based molecular docking approach was used to screen compounds against the protein 
SSH1, which has been shown to play a role in Aβ accumulation. Compounds were chosen from 
the docking results and several inhibitors were identified. One of these compounds was found to 
be a direct inhibitor of SSH1 activity, and resulted in reduced levels of Aβ production. Efforts 
are underway to determine the structure of the inhibitors in complex with SSH1. 
 
Introduction 
 The accumulation of Aβ and Tau are often considered the defining pathological 
hallmarks of AD, with accumulations of Aβ (known as plaques) found outside neurons, and 
accumulations of Tau (known as tangles) found inside neurons.14-17 To date, post-mortem 
identification of Aβ plaques and Tau tangles in the brain is the only method to definitively 
diagnose AD.16 Aggregation of Aβ gives rise to toxic forms of the protein, such as dimers, 
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oligomers, and fibrils, with synapses generally agreed to be the target of Aβ toxicity.15,129 The 
exact method by which Tau exerts its neurotoxic effects is not fully understood, but it is known 
that Tau becomes increasingly hyperphosphorylated in the brains of AD patients.15,16,130 It has 
been shown that Aβ toxicity requires the presence of Tau, as many of the deleterious effects of 
Aβ accumulation are not observed in Tau’s absence.131 However, despite the link between Aβ 
and Tau, the identity and role of many of the molecular intermediates between the two are not 
clearly understood. 
 
 Role of SSH1 
 Slingshot Phosphatase 1 belongs to a family of dual-specificity protein phosphatases, and 
has a major role in the regulation of actin dynamics by dephosphorylating and activating 
Cofilin.132,133 Cofilin binds to actin and promotes actin assembly and disassembly dynamics, with 
actin dynamics playing critical roles in multiple cellular events.132 Cofilin is inactivated by 
phosphorylation at Ser3 and is reactivated upon dephosphorylation by SSH1 or the other 
Slingshot family members, SSH2 and SSH3.132,133 The SSH family of proteins has a 
characteristic N-terminal noncatalytic domain and a catalytic C-terminal domain that contains 
the catalytic Cys393 residue.133 
 Both Aβ and Tau have been shown to promote Cofilin-Actin pathology, and this 
pathology is widespread in the brains of AD patients.134-136 Additionally, the activity of Cofilin is 
significantly increased in the brains of AD patients.137 During oxidative stress or Ca2+ elevation 
caused by increased Aβ levels, SSH1 becomes activated and dephosphorylates Cofilin.134,137,138 
The activation of Cofilin ultimately results in the increase of Aβ levels, which in turn causes 
more SSH1 to be activated and leads to the activation of more Cofilin, thus creating a cycle 
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(Figure 32). The activation of Cofilin also leads to the hyperphosphorylation of Tau, which is 
commonly seen in AD brains. Previous studies have shown that both SSH1 and Cofilin are 
needed for Aβ production, and that some of the deleterious effects of Aβ production were 
lowered when levels of activated Cofilin fell. The SSH1-Cofilin activation pathway appears to be 
at the center of Aβ production and the manifestation of its neurotoxic effects. Inhibition of this 
pathway through the discovery of novel inhibitors against SSH1 could lead to a therapy that can 
directly effect Aβ levels, and thereby mitigate its neurotoxic effects. 
 
Results and Discussion 
 
 Virtual Screening 
 There is no known structure of SSH1; therefore, a homology model of SSH1 was 
constructed to enable molecular docking to be carried out. SSH2 is highly homologous to SSH1, 
and unlike SSH1, the structure of the catalytic domain has been previously determined (PDB 
2NT2).139 SWISS-MODEL was used to construct a homology model of the SSH1 catalytic 
domain based upon the SSH2 structure. Fragment based molecular docking was then carried out 
against SSH1 by targeting the catalytic domain, with focus placed on the subpocket that 
recognized the phosphate moiety of the substrate (residues 393-399). Many fragment and lead-
like compounds were found to complement this site, and 40 were selected from the docking 
results for inhibitor testing. 
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Protein Purification 
 Expression and purification of the SSH1 catalytic domain proved to be challenging, with 
multiple constructs designed and several protocols attempted before a suitable combination of 
construct and purification strategy was determined. In the literature, SSH2 is a C393S mutant as 
this mutation was required to grow well-diffracting crystals, possibly due to the oxidation of the 
cysteine residue in the WT.139 Although the C393S mutation was reported to improve 
crystallization in SSH2, initial attempts were made to purify and crystallize SSH1 without this 
mutation, but expression of the protein failed. After several attempts, the C393S mutation was 
added back to the protein, and upon this addition, SSH1 was successfully expressed.  
 After overcoming the issue of protein expression, efforts were focused on determining 
the optimal purification strategy. This too proved to be challenging, as SSH1 was not entirely 
stable in the purification buffers, leading to issues with solubility throughout the purification. In 
initial purification trials, a nickel-affinity column was used, followed by removal of the His-Tag, 
then a second run through a nickel-affinity column again, followed by a final gel filtration 
column. Unfortunately, the final SSH1 sample obtained still contained a relatively high amount 
of impurities, and rapidly crashed out of solution after 24-48 hrs. To overcome this issue, the use 
of an ion-exchange column was added to the purification protocol. The use of an anion-exchange 
column after TEV cleavage and the second run on the nickel-affinity column greatly improved 
the purity of the sample, and at the same time increased the solubility of the protein. The increase 
in solubility may have been a result of the improved purity of the sample. When adding the 
anion-exchange column to the protocol, the final SSH1 sample obtained after the use of the gel 
filtration column was both pure, and relatively stable in the storage buffer, with it crashing out of 
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solution after about a week instead of a day or two. The increased purity and solubility would be 
critical during crystallization screening. 
 The SSH2 catalytic domain was also purified using the same purification strategy. The 
high homology between the active sites for SSH1 and SSH2 led to the belief that any selected 
compounds found to bind to, and inhibit, SSH1 could also potentially bind to SSH2. With SSH2 
already proven to yield diffraction quality crystals in the literature, it was purified as a backup in 
case SSH1 crystallization trials failed to provide any hits. Additionally, the full-length version of 
SSH1 was purified, but was found to be relatively impure compared to the final SSH1 catalytic 
domain sample. Repeated efforts failed to improve the purity of the full-length SSH1, so it was 
used in the activity assay, and not for crystallization screening. 
 
 Compound Testing 
 The activity of the 40 compounds selected from the docking results was assessed using 
several cell-based assays. Three compounds (5A, 3B, and 4B. See Note to Reader #2) were 
found to inhibit Aβ induced (Figure 32) Cofilin dephosphorylation at 1 and 10 µM, and several 
other compounds were found to produce the same results at concentrations > 10 µM. Compound 
5A was chosen for further testing, and found to directly inhibit SSH1 in a dose-dependent 
manner. Further compound testing using analogs of compounds selected from initial docking 
results is currently underway. 
 
 Protein Crystallization 
 In an effort to solve the structure of SSH1 in complex with the newly discovered 
inhibitors, crystallization screening experiments using the SSH1 and SSH2 catalytic domains 
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were carried out, and each protein was screened against over 1000 crystallization conditions at 
20° C. After four days, many conditions were found in which SSH1 had formed initial 
crystallization hits, with one condition forming small, rectangular shaped crystals. Attempts were 
made to scale this condition up and grow larger diffraction quality crystals but, thus far, all 
attempts have been unsuccessful. Additional attempts to optimize and scale this condition up, as 
well as identify new SSH1 crystallization conditions, are currently underway. 
 Crystallization screening with SSH2 fared better, as two conditions were identified that 
yielded clusters of large rectangular crystals after 1-4 days (Figure 33). The sizes of the crystals 
were suitable for diffraction experiments, but they were growing in clusters and not individually. 
The clusters were used as seeds and experiments were carried out in an attempt to grow large, 
individual, SSH2 crystals. Seeding failed to improve the crystal quality in the first condition, and 
continued to form clusters of SSH2 crystals. However, the second condition produced large, 
single, diffraction quality crystals when seeding was used (Figure 34). These large individual 
crystals were used in diffraction experiments, and the highest resolution dataset collected 
measured 1.91 Å. Attempts to solve the complex structure of the newly discovered inhibitors 
bound in the SSH2 active site are currently underway. 
 With SSH2 successfully crystallized, attempts were made to use SSH2 seeds to promote 
SSH1 crystal growth. A seeding tool was used to transfer seeds from the SSH2 crystallization 
condition into the SSH1 condition identified from screening. The use of SSH2 seeds failed to 
promote SSH1 crystal growth in the identified SSH1 condition. As the SSH1 crystallization 
condition differed from the SSH2 crystallization condition that the seeds were grown in, it is 
possible that the seeds were unstable in the SSH1 condition and disassociated before SSH1 
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crystals could form. Attempts are currently being made to determine if SSH2 seeds can promote 
SSH1 crystal growth in the SSH2 crystallization condition. 
 
Conclusions 
 Structure based drug design was carried out against SSH1 in order to identify novel 
inhibitors. Three inhibitors were discovered through the use of a fragment based molecular 
docking approach. These three inhibitors were found to inhibit Aβ induced Cofilin 
dephosphorylation at 1 and 10 µM, and one of these compounds was also found to directly 
inhibit SSH1. Crystallization of SSH1 is still ongoing, but crystals of the homolog, SSH2, have 
been successfully grown. The high homology between the SSH1 and SSH2 active sites may 
allow the inhibitors to bind to the SSH2 active site. Efforts are currently underway to solve the 
structure of SSH1, or SSH2, in complex with the newly discovered inhibitors. The three newly 
discovered inhibitors represent promising lead structures in the development of a high affinity 
SSH1 inhibitor, and in the development of an effective AD therapy. 
 
Experimental Procedures 
 
 Virtual Screening 
 Virtual screening was performed using the program DOCK 3.5.54. The ZINC database 
fragment and lead-like subsets were docked into the active site of the SSH1 homology model. 
There were no ions or waters present in the homology model. The program Dockblaster5c was 
used to generate matching spheres, with a total of 60 spheres used for each docking run. The 
grids used to score the binding poses were calculated by summing the energies calculated by 
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DISTMAP (excluded volume grid), CHEMGRID (VDW potential), and DelPhi (desolvation). 
Scored compounds were visually inspected using Pymol. 
 
 Protein Purification 
 The SSH1 gene was cloned into a pET15-MHL vector and then transformed into E. coli 
Rosetta (DE3) pLysS cells for expression. Cells were cultured in LB broth containing 50 µg/ml 
ampicillin, 50 µg/ml chloramphenicol, and 85.56 mM NaCl, at 37° C with shaking at 225 rpm, 
until the OD600 reached 0.6-0.8. Overexpression of the SSH1 protein was induced with 5 mM 
IPTG at 20° C, and with shaking at 225 rpm, overnight. Cells were then harvested by 
centrifugation at 5000g, for 10 min, at 4° C. The pellet was resuspended in Buffer A (20 mM 
Tris pH 8.4, 300 mM NaCl, 10% (v/v) Glycerol, 10 mM Imidazole, 0.05% β-ME) and a protease 
inhibitor tablet was crushed and dissolved in the resuspension. The resuspended cells were lysed 
by sonication using a program of 10 sec ON and 15 sec OFF at amplitude 6, for a total of 15 min. 
Cell lysate was cleared by ultra-centrifugation at 40,000 rpm for 35 min at 4° C. The lysate was 
then filtered. 
 The protein sample was loaded onto a 5 ml HisTrapHP nickel-affinity column at 1.0 
ml/min using an AKTA Explorer 100 system. After loading, the column was washed with Buffer 
A at 2 ml/min until the UV280 reading baselined. Protein was eluted from the column using an 
increasing concentration of Buffer B (20 mM Tris pH 8.4, 300 mM NaCl, 10% (v/v) Glycerol, 
500 mM Imidazole, 0.05% β-ME) from 0-100% over 100 min, at 1.0 ml/min. Fractions were 
tested for the presence of SSH1 by SDS-PAGE. The SSH1 containing fractions were pooled, and 
then underwent buffer exchange with Buffer A until the final imidazole concentration was < 5%. 
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TEV protease was added to the protein in a 1:10 ratio by weight (TEV mg:SSH1 mg) to cleave 
the His-Tag off SSH1. The TEV cleavage reaction was allowed to proceed overnight at 4° C. 
 After running overnight, the reaction solution was filtered to remove any precipitation 
and then loaded onto a 5 ml HisTrapHP column at 0.5 ml/min. The column was then washed 
with Buffer A until the UV280 reading baselined, followed by a wash with 5% Buffer B. The 
flow-through and wash were collected and pooled, with SSH1 presence confirmed by SDS-
PAGE. The sample underwent buffer exchange using Buffer QA (20 mM Tris pH 8.2, 1 mM 
EDTA, 1 mM DTT) until the salt concentration was < 10 mM. The sample was then loaded onto 
a 1 ml MonoQ anion-exchange column at 1.0 ml/min. Protein was eluted from the column using 
an increasing concentration of Buffer QB (20 mM Tris pH 8.2, 500 mM NaCl, 1 mM EDTA, 1 
mM DTT) from 0-100% over 100 min, at 1.0 ml/min. Fractions were tested for SSH1 presence 
by SDS-PAGE, and then protein containing fractions were pooled.  
The protein was concentrated to 3 ml for loading onto a 124 ml SuperDex75 16/60 gel 
filtration column. Sample was loaded onto the column, and then run at 0.5 ml/min using Buffer 
C (20 mM Tris pH 8.2, 100 mM NaCl, 1 mM EDTA, 1 mM DTT). Eluted fractions were tested 
for purity by SDS-PAGE, and pure SSH1 fractions pooled. The pooled fractions were 
concentrated, aliquoted, and flash frozen. This purification strategy was used for the purification 
of SSH1 and SSH2. 
 
Protein Crystallization 
 SSH1 and SSH2 were screened individually against multiple crystallization screening kits 
from Qiagen (over 1000 conditions total), through the use of the Art Robbins Instruments 
Phoenix liquid-handling platform. Screening drops (0.4-0.8 µl volume) were set up in 1:1 and 
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2:1 ratios (SSH1 or SSH2:crystallization condition) using 18 mg/ml SSH1 and 17-19 mg/ml 
SSH2. Crystallization screens were incubated at 20° C, and checked daily for the next two 
weeks. Several conditions were found to produce SSH1 crystals after four days, with the best 
condition (0.2 M MgCl2, 0.1 M Tris pH 8.5, and 30% (w/v) PEG 4000) producing small 
rectangular crystals. Initial attempts to scale this condition up (2-4 µl volume) and produce larger 
crystals were unsuccessful, but further optimization of this condition and additional attempts to 
scale it up are currently underway. 
 Screening with SSH2 lead to the identification of two conditions that produced clusters of 
large rectangular crystals 1-4 days after screening. The first condition identified was 0.2 M 
Sodium Acetate, 0.1 M Tris pH 8.5, 30% (w/v) PEG 4000. The second condition identified was 
0.1 M Bicine, 30% (w/v) PEG 6000, final pH 9.0. Both conditions were successfully scaled up 
and again produced clusters of large rectangular crystals. The clusters of crystals produced by 
both conditions were crushed thoroughly and used as seeds in order to increase crystal size and 
promote individual growth (as opposed to clusters). The seeds were diluted 1:100 and 1:1000 in 
the respective crystallization buffers, and then drops were set up using the seed dilutions and 
fresh protein. The use of seeds failed to improve the quality of crystals obtained using the first 
condition, as crystals continued to grow as clusters. However, the use of seeds greatly improved 
the quality of crystals produced using the second condition, with the crystals growing as large 
individual rectangles that were deemed suitable for initial diffraction experiments. Crystals were 
transferred to drops containing the crystallization condition and 30% glycerol, and then 
harvested and cryo-cooled using liquid nitrogen. 
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 X-Ray Data Collection and Structure Determination 
 X-ray diffraction data for SSH2 were collected at the SER-CAT 22-ID beamline at the 
Advanced Photon Source (APS) at Argonne National Laboratory. HKL2000 was used to process 
the diffraction data,94 and the highest resolution dataset was found to be 1.91 Å. Structure 
determination is currently ongoing. 
 
Note to Reader #1 
 The project described in this chapter was developed in collaboration with the Kang lab, at 
the University of South Florida. The Kang lab was responsible for the determination of the 
SSH1-Cofilin pathway, as well as all inhibitor testing. 
 
Note to Reader #2 
 Due to licensing considerations, the structures for compounds 5A, 3B, and 4B cannot be 
shown. However, the molecular weights for the compounds are as follows: 5A) 342.32, 3B) 
339.35, and 4B) 297.31.  
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Figure 32. Proposed SSH1-Cofilin Pathway. Upon oxidative stress 
or calcium ion elevation as the result of increased Aβ levels, SSH1 
becomes activated. When activated, SSH1 dephosphorylates Cofilin, 
resulting in Cofilin activation. Cofilin activation ultimately results in 
the further increase of Aβ levels, which in turn leads to the activation 
of more SSH1. 
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Figure 33. Initial SSH2 Crystals. Initial SSH2 crystals produced by both identified 
conditions grew as clusters of rectangular crystals. 
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Figure 34. SSH2 Crystals Grown from Seeds. 
When using seeds obtained from original clusters, 
the second identified SSH2 condition produced large 
rectangular crystals. 
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Chapter 5: 
 
Summary 
 
 Structure based drug design was used in three different projects in an attempt to identify 
novel inhibitors, and to study the interactions these inhibitors have with their target active site in 
order to optimize their affinity. The first project focused on the interactions a novel 
organometallic β-lactam compound had with the active site of CTX-M-14 E166A β-lactamase. 
The determination of three crystal structures showing products of the compound in complex with 
CTX-M helped to demonstrate the value of the organometallic ruthenocene group to drug 
discovery. The high resolutions of these structures also allowed for the elucidation of the 
hydrogen bonding network in the CTX-M active site upon substrate binding, and subsequent 
determination of the general acid proton source in the CTX-M catalysis reaction. Insights were 
also made into the formation of a special type of hydrogen bond, and the possibility of a form of 
product inhibition occurring. The findings from this project will help to guide future drug 
discovery efforts against CTX-M and PBPs. 
 The second project focused on novel inhibitor discovery against three different PBP 
targets through the use of a fragment based molecular docking strategy. All three targets were 
successfully purified and crystallized, and an activity assay developed for each. However, thus 
far, no inhibitors against any of the targets have been identified. The successful purification and 
crystallization of the proteins overcomes a significant hurdle in the structure based drug design 
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process, and it is likely that further rounds of virtual screening, which are currently underway, 
will lead to the identification of inhibitors against each target.  
 The final project focused on novel inhibitor discovery against a protein involved the 
manifestation of Alzheimer’s disease. Through the use of a fragment based molecular docking 
strategy, three compounds were identified as potential inhibitors of this protein, and the pathway 
it is involved in. Purification and crystallization of the target protein, and a close homolog, was 
successfully completed, and efforts to solve the structure of the newly identified inhibitors in 
complex with the target protein, or its homolog, are currently underway. The identified 
compounds will serve as excellent starting points in the development of an effective therapy 
against Alzheimer’s disease. 
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Appendix 4: 
 
Compounds Tested Against MTG 
# Name Ki (µM) Structure 
1 ZINC04343488 No 
Inhibition 
	  
2 ZINC30695513 No	  Inhibition	  
	  
3 ZINC17013522 No 
Inhibition 
	  
4 ZINC22279548 No 
Inhibition 
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5 ZINC15777317 No 
Inhibition 
	  
6 ZINC32559948 No 
Inhibition 
	  
7 ZINC19505337 No 
Inhibition 
	  
8 ZINC05480979 No 
Inhibition 
	  
9 ZINC36392890 No 
Inhibition 
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10 ZINC04076397 No 
Inhibition 
	  
11 ZINC44460445 No 
Inhibition 
	  
12 ZINC47929393 No 
Inhibition 
	  
13 ZINC05728952 No 
Inhibition 
	  
14 ZINC16137380 No 
Inhibition 
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15 ZINC70655883 No 
Inhibition 
	  
16 ZINC16952860 No 
Inhibition 
	  
